

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Autonomy to adhere to non-pharmaceutical interventions on COVID-19 infections in the first year of the pandemic in the UK

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-054200
Article Type:	Original research
Date Submitted by the Author:	05-Jun-2021
Complete List of Authors:	Ding, Xuejie; University of Oxford Brazel, David M.; University of Oxford Mills, Melinda; University of Oxford
Keywords:	COVID-19, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Public health < INFECTIOUS DISEASES, PUBLIC HEALTH





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

Autonomy to adhere to non-pharmaceutical interventions on COVID-19 infections in the first year of the pandemic in the UK

Xuejie Ding,^{a,†} David M. Brazel,^a and Melinda C. Mills^{a,†}

^a Leverhulme Centre for Demographic Science and Nuffield College, University of Oxford,

UK

⁺ corresponding authors: <u>xuejie.ding@sociology.ox.ac.uk</u> and <u>melinda.mills@nuffield.ox.ac.uk</u>

Funding

Funding is provided by the Leverhulme Trust and ERC Advanced Grant (835079) to MCM. The funders had no role in study design, data collection, analysis, interpretation, or writing.

Contributions

MCM, XD, DMB designed the study and MCM wrote the report, to which all authors contributed. MCM, XD and DMB designed the models. XD and DMB prepared the data and ran the models. MCM designed the time-varying graphic. All authors read and approved the final article.

Declaration of interests

MCM is a member of the UK Scientific Advisory Group for Emergencies sub-groups SPI-B (behavioural insights), ethnicity and Vaccines Science Coordination Group and member of the Royal Society's SET-C (Science in Emergencies Tasking – COVID) group, all which respond to requests from government departments and the Government Office for Science.

Data Sharing

This work contains statistical data from Office of National Statistics (ONS) which is Crown Copyright. The use of the ONS statistical data in this work does not imply the endorsement of the ONS in relation to the interpretation or analysis of the statistical data. This work uses research datasets which may not exactly reproduce National Statistics aggregates. The Covid Infection Study (CIS) data are available via a formal request to the ONS Secure Research Service for accredited researchers.

Acknowledgements

This work was supported by the Leverhulme Trust, Leverhulme Centre for Demographic Science (Grant number N/A) and ERC Advanced Grant (835079).

Number of figures: 3

Word counts: 3,900

Competing interest statement:

The authors declare no competing interest.

Non-pharmaceutical interventions (NPIs) have been introduced to control SARS-CoV-2 infections, we provide individual-level empirical evidence of whether adherence reduces infections.

Setting and participants

ABSTRACT

Objective

The Covid-19 Infection Study (CIS) was used from 10 May 2020 to 02 February 2021 with 409,009 COVID-19 nose and throat swab tests nested in 72,866 households for 100,138 individuals aged 18-64.

Analysis

Odds ratios (ORs) for a positive COVID-19 test were calculated using multilevel logistic regression models, stratified by sex and time, by an index of autonomy to abide to NPIs, adjusted for various socioeconomic and behavioural covariates.

Results

Inability to comply with NPIs predicts higher infections when individuals reported not wearing a face-covering outside. The youngest 18-29 age groups had a significantly higher risk of infection, with larger households having significantly higher infections for women. Male smokers had a significantly lower risk. Effects varied over time with autonomy to follow NPIs only significant in the pre-second lockdown May- November 2020 period. Wearing a face covering outside was a significant predictor of lower chance of infection before mid-December 2020 when a stricter second lockdown was implemented. Black, Asian and minority ethnic groups were more likely to be infected. The random effects variance estimates were larger at the household than the individual level OR: 3.34 (95%CI 3.05 to 3.63) versus OR: 1.02 (95% CI 0.78 to 1.26), suggesting that there is more unexplained variation in infection risk in households.

Conclusion

The inability to comply with NPIs results in higher COVID infections only when individuals do not adhere to protective. Higher infection rates are in younger groups, women in large households and vary by time and type of lockdown restriction, with wearing a face-covering or mask outside the home consistently and significantly predicting lower infection among females and before the 2020 Christmas.

Strengths and limitations of this study

- Our study is that it is to our knowledge the first large-scale study that links the reporting of individual and household level adherence to NPIs and their ability or challenges to adhere to actual measured infections.
- This representative population-based study went beyond the self-reporting of SARS-CoV-2 to use throat and swab SARS-CoV-2 positivity testing opposed to population-wide case data, which is subject to significant selection bias. This is also an advantage over other measures such as hospitalisation or death, which only pick up the most severe cases.
- By measuring infections in this manner, we are also able capture those who might be asymptomatic or whose infections are relatively mild.
- Although the dataset is the most representative data to date, some groups such as ethnic minorities (termed BAME in the UK) is still underrepresented in the sample.
- Participation in the study is voluntary and thus self-selection bias may affect the results.
- Finally, as others have noted, we are unable to determine the sensitivity and specificity of the PCR test, but it is likely close to 100%.

INTRODUCTION

 Although most countries have introduced non-pharmaceutical interventions (NPIs) to lower the spread of infectious diseases such as SARS-CoV-2, there is limited empirical research on the relationship of adherence to infections or how an individuals' autonomy or ability to follow measures relates to infections,[1]. To form evidence-based health policy, it is crucial to have empirical evidence that tests whether the adherence to NPIs is effective in reducing infection. The lack of compliance to NPIs has been generally positioned as an attitude or choice,[2], but it may be related to the inability to follow measures and exacerbate existing health inequalities. This includes employment that does not accommodate working at home, the necessity to take public transport, or being in workplaces or households where recommended social distancing is not possible.

Due to data limitations, existing research examining the effects of NPIs on COVID-19 related outcomes has almost exclusively used aggregated data to model the correlation between the timing of various national, state or regional level NPIs with COVID-19 case rates,[1,3-6]. These types of studies risk producing an ecological fallacy, since the interpretation of statistical data about individuals are deduced from an inference for the group to which those individuals belong to,[1]. In the early stages of the pandemic in 2020, some simulations also estimated the potential ebb and flow of infections in relation to the introduction of various NPIs and how this might impact healthcare demands,[7]. There have been various systematic reviews and meta-analyses, some with mixed results, but generally demonstrating the protective nature of NPIs,[8,9]. Other studies examining the effectiveness of face coverings and masks have been largely carried out in health settings examining N95 or surgical masks, with critiques that findings cannot be transferred to community settings or do not properly control for confounders,[9].

Although a handful of individual-level studies more directly examined the relationship between individual adherence NPIs and individual-level case data of infections, they were carried out in the early stages of the pandemic, had small samples (1,000,[10] or 1,500 cases,[11]), and used general NPI measures. A previous review concluded that although many studies have assessed NPIs, few were able directly examine or quantify their impact,[12]. We aimed to measure the association between COVID-19 infections and the autonomy to follow NPIs, key sociodemographic factors, and changes over time, using individual- and household-level data in a large nationally representative sample in the UK collected over almost one year from May 2020 to February 2021.

METHODS

Study design and participants

The Covid Infection Study (CIS) is one of the largest regular surveys of coronavirus infections and antibodies,[13]. The CIS has been used to examine multiple aspects of the pandemic and to monitor community prevalence of SARS-CoV-2 infection,[14]. Samples, demographic information and a short questionnaire are collected from individuals aged 2 and older living in private households in England, randomly selected from address lists and the Office of National Statistics (ONS) surveys. It is a repeated household survey with additional serial sampling and longitudinal follow-up. Data includes a questionnaire and nose and throat swabs. If multiple household members agreed to participate, a home visit was made to collect information. Following the first visit, participants who agree, are visited every week for the first five weeks and then receive optional monthly visits. All study protocol and questionnaires are available online (<u>https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey</u>).

A positive COVID-19 test was determined from nose and throat swabs using the TaqPath RT-PCR COVID-19 kit (Thermo Fisher Scientific, Waltham, MA, USA), analysed using UgenTec Fast Finder 3.300.5 (TaqMan 2019-nCoV assay kit V2 UK NHS ABI 7500 v2.1; UgenTec, Hasselt, Belgium), described in detail in the sources listed above. Tests are considered positive when at least one gene is present – N, ORF1ab, or both – but could be accompanied by the gene for S protein (detection of S protein alone is not considered reliable),[14]. For the analyses in this study, the Covid-19 Infection Study (CIS) from 10 May 2020 to 02 February 2021 was used with 409,009 valid COVID-19 tests from nose and throat swabs nested in 72,866 households for 100,138 individuals aged 18-64 years.

Statistical analysis

We estimated the likelihood of testing positive for SARS-CoV-2 from nose and throat swabs using three-level multivariate multilevel logistic regression models, also stratified by sex and time period. The outcome is a positive Covid-19 test, with the main predictors of sex, Black, Asian or minority ethnicity (BAME), age group, visit date, household size, smoking status, region, occupation, days since contact with any COVID-19 positive person, compliance with wearing a face covering or mask and autonomy to comply with NPIs.

Autonomy to adhere to NPIs is measured via the sum of several situations that might limit the respondents' ability to comply. Each situation is assigned points which is then summed into one index. These include that the respondent reports it is: 1) possible to work outside the home at least one day per week (1 point), 2) 'easy to maintain 2 metres' distance in workplace (0 points), 3) 'relatively easy to maintain 2 metres' distance in the workplace (1 point), 4) 'difficult to maintain 2 metres, but can be 1 metre' in the workplace (2 points), 5) 'very difficult to be more than 1 metre away' in the workplace (3 points), 6) a main working location that is 'somewhere else (not your home)' (1 point), 7) common to go to and from work/school by bus, coach or minibus (1 point); and, 8) work that involved direct contact with patients, clients, residents, service users or customers on a day-to-day basis (1 point). We included transportation by bus, coach or minibus only since sensitivity analyses that included other means of transportation such as underground, tram or motorbike, scooter, or car all showed a reverse correlation with other autonomy items and reduced the reliability of our autonomy index. The autonomy index passed the Cronbach's alpha test with the reliability coefficient of 0.73.

To interpret the index, for instance, a person who reports working outside home for 5 days a week (+1), who working in a job where it is difficult to maintain 2 metre distancing, but can maintain 1 metre (+2) and whose main work location is not home (+1) and does not take public transportation of a bus (0'), but works directly with people (+1) will score 5 in autonomy. After summing the scores, we reverse coded the autonomy variable so that a lower score indicates low autonomy (i.e., more situations that limit the individuals' ability to comply) and a higher autonomy score indicates a better ability to comply with NPIs. The range for the autonomy variable is from 0-7, with the person described in the previous example is scored 2 given reverse coding.

Mixed-level logistic regression models were estimated with COVID-19 tests (level 1) nested within individuals (level 2) nested within households (level 3) with the outcome variable of COVID-19 positive infections. The main model estimates sex, ethnicity, age group, reporting to wear a face covering or mask, our autonomy to comply index and additional control variables. Model 2 adds an interaction term between autonomy to adhere and wearing a face

covering or mask. Model 3 is the same as model 2 but only includes females. Model 4 is the same as the main model but only includes males. We estimated sex-specific models since when we added the interaction term for men only in the model, the interaction terms were not significant, the model fit did not increase, and the main effect also disappeared. We therefore consider the interaction terms in the male model as an unnecessary control and only reported the main models for men. Next, we stratified the models by three periods that broadly reflect the various phases of restrictions in the UK of: 1) 10 May - November 04 (pre-lockdown 2), 2) 05 November to December 19 (lockdown 2 'light version'), and 3) 20 December to Feb 02 (Lockdown 2 stricter) (See Figure 1). These periods follow the general guidelines, which varied somewhat across the four nations of England, Scotland, Wales and Northern Ireland. For the first periods, we were able to fit the model with the interaction term, and for the second and third period we fit the main model without the interaction term for the same reason mentioned above in relation to sex. Occupation was not included in the models by time periods due to the small sample sizes in each categories.

Patient and public involvement

Patients and the public were not involved in the development of research questions, design of the study, recruitment, and conduct of the study, or dissemination of the study results.

RESULTS

We find that the level of autonomy to adhere to NPIs does not predict COVID-19 infection alone, rather the risk of infection is lessened when individuals comply to NPIs (Figure 2, or Table S1). Autonomy to comply with NPIs predicts higher infections (OR: 0.79; 95% CI 0.67 to 0.92) when individuals do not engage in protective measures of wearing a face covering or mask outside. We visualise this interaction effect based on model 3 in Figure 3. The interaction effect is the most prominent among females.

The youngest 18-29 year old age groups have a significantly higher odds of infection (OR 1.17; 95%CI 1.00 to 1.37), with living in a larger household only related to a significantly higher odds of infection for women (OR: 1.04; 95%CI 1.02 to 1.06). Male smokers had a significantly lower risk (OR: 0.84; 95%CI 0.74 to 0.94]). This is in line with a recent review of 17 studies that also found that current smokers had a reduced risk of testing positive for COVID-19,[15].

To test whether our key predictors change in relation to key policy restrictions put in place to restrict infections, hospitalisation and deaths (Figure 1, or Table S2), we divided the analysis into three policy periods (available in our data) of: (1) 10 May 2020 - 04 November 2020 (first lockdown to pre-second lockdown), (2) 05 November – 19 December (second lockdown and pre-Christmas period of 'lockdown light'); and, (3) 20 December – 02 February (stricter second lockdown with schools closed and introduction of Tier 4). Figure 1 illustrates the clear time-lag between infections leading to deaths, with the expectation that this will be disrupted by vaccinations as time elapses. Black, Asian and minority ethnic groups are more likely to be infected, especially during the second lockdown (05 Nov-19 December) (OR: 1.36; 95%CI 1.04 to1.79).

Effects varied over the year with autonomy to follow NPIs only significant in the pre-Second lockdown period (May- November 2020). Wearing a face covering or mask outdoors was a significant predictor of a lower chance of infection before 19 December 2020 (OR: 0.44; 95%CI 0.27 to 0.73) when a stricter second lockdown was implemented. One possible explanation is that the percentage of people not wearing face covering/masks was low and declined from 2% to 1% from May 2020 to Feb 2021. The variable may also be capturing

4

5

6 7

8

9

11

17

18

19

20

21

22

23

24 25

26

27

28

29

30 31 32

33

34

35

36

37

38

39 40 41

42

43

44

45

46

47 48 49

50

51

52

53

54 55

56

57

58

59

60

both the social environment (i.e., wearing a face covering may be influenced on the level of individuals wearing masks around you) and correlated health behaviours (i.e., those who wear face coverings are more cautious in other ways). In the full models, the random effects variance estimates were larger at the household level than at the individual level OR: 3.34 (95%CI 3.05 to 3.63) versus OR: 1.02 (95% CI 0.78 to 10 1.26), suggesting that more unexplained variation in infection risk exists at the household level. This difference was smaller or non-existent in the sex-stratified models, with the 12 residual intraclass coefficients also reflecting a loss of household information. 13 14 DISCUSSION 15 16

Using multivariate multilevel logistic regression models, we examined the relationship between individual adherence to NPIs and COVID-19 infection, controlling for key sociodemographic, behavioural and time-related policy changes. We found that autonomy to comply with NPIs predicts higher infections when individuals do not engage in other protective measures of wearing a face covering or mask outside their home. Our results suggest that engaging in protective behaviours such as face coverings can reduce the unequal effects of exposure to COVID-19, noted in previous literature reviews, [9]. Our findings emphasise the need to move to more complex models beyond comparing aggregated percentages of general population compliance to a more nuanced understanding that stratifies groups in meaningful ways to develop tailored health policy interventions and communications. We found that women living a larger household had a significantly higher risk of infection, reflecting more domestic and care duties and time in the household, but also multiple individuals leaving and returning the home from diverse environments.

The 18-29 year old age group had a significantly higher risk of infection, suggesting that this is an important group to consider given that many countries are engaging in age-related vaccine roll-outs. Effects varied over the year with autonomy to follow NPIs only significant in the pre-Second lockdown period (May- November 2020). This was a period where initially many UK governments were reluctant to introduce certain policy interventions, such as the relatively late introduction of face-coverings for the general public in late June or July 2020, first in public transport only,[2].

Wearing a face covering or mask outside the home was a significant predictor of a lower chance of infection before 19 December 2020 when a stricter second lockdown was implemented. BAME groups are more likely to be infected, especially during the second lockdown (05 Nov-19 December). We note, however, that although we see some period variation, given the overlap in CIs and the fact that we are not strictly testing a difference between the coefficients in our model, they are not statistically different.

A strength of our study is that it is to our knowledge the first large-scale study that links the reporting of individual and household level adherence to NPIs and their ability or challenges to adhere to actual measured infections. This representative population-based study went beyond the self-reporting of SARS-CoV-2 to use throat and swab SARS-CoV-2 positivity testing opposed to population-wide case data, which is subject to significant selection bias. This is also an advantage over other measures such as hospitalisation or death, which only pick up the most severe cases. By measuring infections in this manner, we are also able capture those who might be asymptomatic or whose infections are relatively mild. Given the multilevel design based on a sample that was designed to be a random sample of households stratified by gender and time period, we also avoid problems in interpretation over this period due to changes in testing practice. Another advantage is that we have longitudinal, regularly collected data over this period which allows us to examine changes in behaviour over time.

Our study is also subject to several limitations. Although the dataset is the most representative data to date, some groups such as ethnic minorities (termed BAME in the UK) is still underrepresented in the sample. Whereas we have 7% BAME, amongst the UK population, around 14% are from a minority ethnic background. Therefore, our estimates may not reflect the full range of the population. The number of tests in the lockdown 2 'stricter version' period is much smaller, meaning that we may not have the power to detect some effects. Participation in the study is voluntary and thus self-selection bias may affect the results. Finally, as others have noted, we are unable to determine the sensitivity and specificity of the PCR test, but it is likely close to 100%,[16].

The results we present here summarise key parts of the analyses we presented to senior decision makers in the UK over February – March 2021, in a context with rapidly evolving information and changes in vaccine deployment and other relevant policies. As the pandemic evolves and politicians and civil servants continue to make difficult decisions on lifting or re-instating NPIs, this study provides novel and nuanced evidence of the relationship of autonomy to follow NPIs with infection varies and where support or public communication could be directed.

CONCLUSION

 Many countries introduced multiple non-pharmaceutical interventions (NPIs) to control COVID-19 infections, hospitalization and deaths and will continue to implement them during vaccine roll-outs. There have been limited empirical studies using individual-level data to examine how individual adherence to NPIs predicts infections by sociodemographic factors, individual autonomy to abide by NPIs and how these relationships change over time in relation to different restrictions.

We move beyond aggregated figures showing macro correlations of NPI policy stringency with national-level COVID-19 outcomes, to produce individual- and household-level models that properly control for confounders, key sociodemographic and behavioural factors and changes in policy interventions over time. Using the Covid Infection Study (CIS) in the UK with almost one year of data from 10 May 2020 to 02 February 2021, with 409,009 valid COVID-19 tests nested in 72,866 households for 100,138 individuals aged 18-64 years, we estimate multivariate multilevel logistic regression models, stratified by sex and time-period. We create a novel index measuring individual autonomy to abide by NPIs index (i.e., ability to work at home and number of days at home, ability to maintain physical distancing at work, travel to work requires public transport, or work involves direct contact).

Although autonomy or inability to abide by NPIs is a significant predictor of higher infection rates amongst certain groups, it does not predict infection alone. Wearing a face covering or mask outside the home can reduce the unequal effects of exposure to COVID-19 due to individual and employment circumstances. Autonomy to follow NPIs was only a significant predictor of infection risk from May to November 2020 but those who reported wearing a face covering or mask outdoors significantly had lower rates of infection for individuals with lower level of autonomy between 10 May to 04 November and for all people between 05 November to 19 December 2020.

The results we present here summarise key parts of the analyses we presented to senior decision makers in the UK over February – March 2021, in a context with rapidly evolving information and changes in vaccine deployment and other relevant policies. As the pandemic evolves and politicians and civil servants continue to make difficult decisions on lifting or reinstating NPIs, this study provides novel and nuanced evidence of the relationship of autonomy to follow NPIs with infection varies and where support or public communication could be directed.

to peer teriew only

References

- 1 Flaxman S, Mishra S, Gandy A, *et al.* Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* 2020; **584**: 257–61.
- 2 Bish A, Michie S. Demographic and attitudinal determinants of protective behaviours during a pandemic: A review. *Br J Health Psychol* 2010; **15**: 797–824.
- Bo Y, Guo C, Lin C, *et al.* Effectiveness of non-pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13 April 2020. *Int J Infect Dis* 2021; **102**: 247–53.
- 4 Islam N, Sharp SJ, Chowell G, *et al.* Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. *BMJ* 2020; : m2743.
- 5 Haug N, Geyrhofer L, Londei A, *et al.* Ranking the effectiveness of worldwide COVID-19 government interventions. *Nat Hum Behav* 2020; **4**: 1303–12.
- 6 White ER, Hébert-Dufresne L. State-level variation of initial COVID-19 dynamics in the United States. *PLoS One* 2020; **15**: e0240648.
- 7 Davies NG, Kucharski AJ, Eggo RM, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Heal 2020; 5: e375–85.
- 8 Chu DK, Akl EA, Duda S, *et al.* Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* 2020; published online June. DOI:10.1016/S0140-6736(20)31142-9.
- 9 Mills MC, Akimova ET, Rahal C. Face masks and coverings for the general public: Behavioural knowledge, effectiveness of cloth coverings and public messaging. 2020 https://royalsociety.org/-/media/policy/projects/set-c/set-c-facemasks.pdf?la=en-GB&hash=A22A87CB28F7D6AD9BD93BBCBFC2BB24.
- 10 Sun K, Wang W, Gao L, *et al.* Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. *Science (80-)* 2021; **371**: eabe2424.
- 11 Jefferies S, French N, Gilkison C, *et al.* COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. *Lancet Public Heal* 2020; **5**: e612–23.
- 12 Imai N, Gaythorpe KAM, Abbott S, *et al.* Adoption and impact of non-pharmaceutical interventions for COVID-19. *Wellcome Open Res* 2020; **5**: 59.
- 13 ONS. COVID-19 Infection Survey. ONS Rep. 2020. https://www.ons.gov.uk/surveys/informationforhouseholdsandindividuals/househol dandindividualsurveys/covid19infectionsurvey (accessed Feb 14, 2021).
- 14 Pouwels KB, House T, Pritchard E, *et al.* Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. *Lancet Public Heal* 2021; **6**: e30–8.
- 15 Simons, D., Shahab, L., Brown, J., & Perski, O. (2020). The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction.
- 16 Cameron-Blake E, et al. Variation in the response to COVID-19 across the four nations of the United Kingdom. 2020 https://www.bsg.ox.ac.uk/sites/default/files/2020-10/BSG-WP-2020-035-v1_0.pdf.

 bmjopen-2021-05

Figure 1. Timeline of key restrictions in England by COVID-19 cases (left) and deaths (right), January 01 2020 to March 08 2021


Note: JCVI (Joint Committee on Vaccination and Immunisation); AZ (Astra Zeneca). Graph produced by authors using policy data for England, ¹/₂₁₈ and official UK Government data on COVID-19 cases and deaths, ¹⁹ smoothed into 14 day rolling means. Deaths are in red (read from right axis) and cases in blue (read from left axis) with magnitudes representing smoothed 14 day Leve was some variab rolling means and not cumulative figures. The restrictions shown here are for England and we note there was some variation in the detail of some policies and slight variation in timing in Scotland, England, Wales and Northern Ireland. ober 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open	bmjopen
BMJ Open Figure 2. Three-level logistic regression models of COVID-19 positive tests, 10 May 2020 – 02 February 2 and interaction effects (see Appendix for full tables) ONS Covid Infection Study	-2021-0542
Figure 2. Three-level logistic regression models of COVID-19 positive tests, 10 May 2020 – 02 February 2 and interaction effects (see Appendix for full tables), ONS Covid Infection Study	25
	October 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright
	om http://bmjopen.bmj.con
	v/ on April 23, 2024 by gu
	est. Protected by copyri
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	역

Page 12 of 30

Page 13 of 30	BMJ Open	bmjope
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Figure 3. Association between infection and autonomy by level of compliance to wearing face covering/mat	-
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33		tp://bmjopen.bmj.com/ on April 23, 2024 by gu
34 35 36 37 38 39 40 41 42 43 44 45	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	lest. Protected by copyright.






Figure 1. Timeline of key restrictions in England by COVID-19 cases (left) and deaths (right), January 01 2020 to March 08 2021

Note: JCVI (Joint Committee on Vaccination and Immunisation); AZ (Astra Zeneca). Graph produced by authors using policy data for England,17,18 and official UK Government data on COVID-19 cases and deaths,19 smoothed into 14 day rolling means. Deaths are in red (read from right axis) and cases in blue (read from left axis) with magnitudes representing smoothed 14 day rolling means and not cumulative figures. The restrictions shown here are for England and we note there was some variation in the detail of some policies and slight variation in timing in Scotland, England, Wales and Northern Ireland.

246x128mm (220 x 220 DPI)





Figure 2. Three-level logistic regression models of COVID-19 positive tests, 10 May 2020 – 02 February 2021 by key fixed-effect predictors and interaction effects (see Appendix for full tables), ONS Covid Infection Study

184x147mm (144 x 144 DPI)

BMJ Open: first published as 10.1136/bmjopen-2021-054200 on 25 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.






Figure 3. Association between infection and autonomy by level of compliance to wearing face covering/masks (estimates from Model 3).

202x145mm (144 x 144 DPI)

Table S1. Multileve										bmjopen-2021-054200		<u> </u>
Outcome: Test positive	Model 1:	Main effec	ct	Model 2:	Interaction	l	Model 3: Female only with interaction			Model 4: effect	Male only	main
I	Odds Ratio	Lower 95% CI	Upper 95% CI	Odds Ratio	Lower 95% CI	Upper 95% CI	Odds Ratio	Lower 95% CI	Upper 95% CI	Odds Ratio	Lower 95% CI	Upp 95%
Female	0.90	0.81	0.99	0.90	0.81	0.99	-	-	-	ber -	-	
BAME	1.17	1.00	1.37	1.17	1.00	1.37	1.17	0.95	1.46	8 1.23	0.99	
Age group (Ref = 60 -	64)									1. D		
18-29	1.52	1.28	1.82	1.52	1.28	1.82	1.58	1.23	2.04	D M 1.40	1.09	
30-39	1.12	0.94	1.33	1.12	0.94	1.33	1.08	0.86	1.37	00 1.15	0.91	
40-49	1.17	0.98	1.40	1.17	0.98	1.40	1.21	0.96	1.53	<u><u></u> 1.08</u>	0.86	
50-59	1.14	0.97	1.33	1.14	0.97	1.33	1.12	0.88	1.41	Tom 1.19	0.94	
Visit date	1.02	1.02	1.02	1.02	1.02	1.02	1.02	1.02	1.02	1.02	1.02	
Autonomy	0.97	0.95	0.99	0.79	0.67	0.92	0.70	0.55	0.88	0.97	0.93	
Face covering or mast Yes my face is				c .		0		0.00		0.97 bmjopen.bmj.com/ 0 84		
already covered Yes at work/school/other	1.01	0.72	1.41	0.37	0.16	0.82	0.23	0.09	0.64	01.02 .00	0.64	
situations only Yes usually both	0.78	0.59	1.02	0.36	0.18	0.71	0.21	0.09	0.49	on 0.84 April 0.71	0.56	
work/school/other	0.70	0.53	0.92	0.29	0.15	0.56	0.18	0.08	0.41	⊡ 0.71 23	0.48	
Autonomy x Face cox Autonomy x Yes my face is already	ering/mask	s (Rei = No	o face cove	ring/mask)						3, 2024		
covered Autonomy x Yes at work/school/other	-	-	-	1.28	1.08	1.53	1.48	1.14	1.91	2024 by guest.	-	-
situations only Autonomy x Yes	-	-	-	1.22	1.04	1.43	1.40	1.11	1.78		-	-
usually both work/school/other				1.25	1.07	1.46	1.43	1.13	1.81	ed		

Page	18	of	30
------	----	----	----

					E	MJ Open				bmjopen-2021-054200 o		
										021-054		
0-14 days	13.74	12.45	15.15	13.74	12.45	15.15	15.03	13.10	17.24	8017.64	15.38	
15-28 days	4.53	3.95	5.19	4.53	3.95	5.19	4.76	3.99	5.68	₹ 5.58	4.59	
29-60 days	1.62	1.38	1.89	1.62	1.38	1.89	1.63	1.32	2.03	²⁵ 2.05	1.62	
61-90 days	0.89	0.69	1.14	0.89	0.69	1.14	1.09	0.78	1.53	0.84 ct 0.84 er 1.14	0.56	
91+ days	1.00	0.76	1.32	1.00	0.76	1.32	0.98	0.66	1.45	₽ 1.14	0.77	
Household size	1.02	0.98	1.06	1.02	0.98	1.06	1.04	1.02	1.06	20 20 1.01	0.95	
Smoke	0.90	0.82	1.00	0.90	0.82	1.00	0.93	0.83	1.05	 0.84 g	0.74	
Region (Ref = Northe	ast)									0.91		
Northwest	1.32	1.07	1.64	1.32	1.07	1.64	1.22	0.93	1.61	oa 1.36	1.02	
Yorks Humber	0.95	0.75	1.20	0.95	0.75	1.20	0.95	0.71	1.28	<u>a</u> 0.91	0.67	
East midlands	0.80	0.63	1.02	0.79	0.63	1.01	0.70	0.51	0.96	fon 0.91	0.65	
West midlands	0.77	0.61	0.98	0.77	0.61	0.98	0.79	0.59	1.07	a 0.71	0.51	
East	0.54	0.43	0.68	0.54	0.43	0.68	0.53	0.39	0.71	0.52	0.38	
London	0.95	0.77	1.18	0.94	0.76	1.17	0.89	0.67	1.17	<u>周</u> . 영 1.01	0.75	
South East	0.69	0.56	0.86	0.69	0.56	0.86	0.68	0.51	0.92		0.50	
South West	0.41	0.32	0.53	0.41	0.32	0.52	0.41	0.29	0.57	0.41	0.28	
Occupation (Ref = He	alth profession	onals)								en.bmj.com/		
Corporate managers and directors	1.79	1.41	2.26	1.77	1.40	2.24	1.86	1.33	2.59	on April April	1.45	
Other managers and proprietors	2.46	1.87	3.24	2.41	1.83	3.17	2.05	1.36	3.10	<u>⊐</u> . 23 3.00	1.91	
Science research engineering and technology		,							3			
professionals Teaching and educational	1.51	1.15	1.98	1.49	1.13	1.96	1.11	0.68	1.80	2024 by guest.	1.31	
professionals Business media and public service	1.60	1.32	1.95	1.58	1.30	1.93	1.43	1.13	1.81	. Protected	1.40	
professionals	1.54	1.19	1.98	1.51	1.17	1.94	1.52	1.09	2.12	1 by copyright.	1.15	

Page 19 of 30						ВІ	NJ Open				bmjopen-		
1 2 3 4 5	Science engineering and technology associate										bmjopen-2021-054200 on		
6 7 8	professionals Health and social care associated	1.51	1.02	2.23	1.49	1.01	2.21	1.38	0.74	2.58	^{N5} 2.01 October 2.16	1.14	3.56
9 10	professionals Protective service	1.48	1.04	2.10	1.46	1.03	2.08	1.30	0.86	1.96	^{er} 2.16	1.15	4.04
11 12	occupations	1.82	1.33	2.49	1.80	1.32	2.47	2.59	1.62	4.14	2022.10 1. 1.86	1.16	2.98
13 14	Culture media and sports occupations Business and public	1.46	1.05	2.04	1.43	1.03	2.00	1.62	1.05	2.49	Downloaded	0.84	2.53
15 16 17	service associated professionals Administrative	1.73	1.37	2.19	1.72	1.36	2.17	1.62	1.18	2.21	fo 2.18	1.45	3.29
18 19	occupations Secretarial and	1.97	1.59	2.45	1.95	1.58	2.42	1.90	1.47	2.45	2.41	1.57	3.71
20 21	related occupations	2.41	1.80	3.23	2.39	1.78	3.20	2.34	1.71	3.20	http://bmjop	0.33	4.54
22 23 24	Skilled agricultural and related trades Skilled metal	0.89	0.46	1.73	0.87	0.45	1.69	1.15	0.33	3.95	1.11 <u>1.11</u> 2.80	0.49	2.52
25 26	electrical and electronic trades Skilled construction	2.25	1.68	3.02	2.20	1.64	2.96	2.92	0.78	10.84	2.80	1.86	4.23
27 28	and building trades Textiles printing and	2.41	1.76	3.30	2.36	1.73	3.23	0.48	0.05	5.06	₽ ₽ 1.32	2.16	5.11
29 30	other skilled trades	1.42	0.87	2.32	1.39	0.85	2.27	1.77	0.89	3.51	, ²³ 1.62	0.80	3.27
31 32 33	Caring personal service occupations Leisure travel and	2.03	1.64	2.52	2.01	1.62	2.50	1.93	1.53	2.45	2024 2.75 gr	1.68	4.48
34	related personal service occupations	1.84	1.17	2.89	1.82	1.16	2.86	1.43	0.80	2.58	guest: 4.31	2.00	9.25
35 36	Sales occupation Customer service	1.95	1.51	2.52	1.92	1.48	2.47	1.72	1.25	2.35	Pot 3.06	1.88	5.00
37 38 39	occupations Process plant and	1.73	1.17	2.57	1.72	1.16	2.54	1.49	0.93	2.39	d 2.77	1.42	5.40
40 41 42	machine operatives	2.10	1.44	3.04	2.05	1.42	2.98	2.94	1.24	6.98	by copyright.	1.54	4.10
42											. t.		

BMJ	Open


Page 20 of 30

					В	MJ Open				bmjope		
										n-2021		
Transport and mobile machine driver and										5.19 pmjopen-2021-054200 on		
operatives Elementary trades and related	2.36	1.76	3.17	2.32	1.73	3.11	1.62	0.64	4.06	on 3.19 25 Oc	2.07	4.91
occupations Elementary	2.75	1.53	4.94	2.69	1.49	4.85	2.92	0.54	15.73	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.78	7.00
administration and service occupations	2.16	1.71	2.73	2.14	1.69	2.71	1.90	1.39	2.60	202 1. 3.03	1.97	4.67
Variance (Household) Residual intraclass correlation	3.34	3.05	3.63	3.34	3.05	3.63	2.38	1.64	3.12	Downloaded	0.94	3.06
(Household) Variance	0.44	0.41	0.47	0.44	0.41	0.47	0.32	0.23	0.42	T ี 0.27	0.15	0.43
(Individuals) Residual intraclass correlation	1.02	0.78	1.26	1.02	0.78	1.26	1.88	1.14	2.62	0.56	1.03	3.19
(Individuals)	0.57	0.55	0.59	0.57	0.55	0.59	0.56	0.54	0.59	0.56	0.53	0.58
N	409,009			409,009			217,920			191,089		
No. of household	72,866			72,866			50,405			4 4,822		
No. of participant	100,138			100,138			53,015			7,123		
										pn April 23, 2024 by guest. Protected by copyright.		

BMJ Open

Table S2. Multilevel logistic r									
Outcome: Test positive	10 May 2020) - 04 Nov 202	0	05 Nov 2020	- 19 Dec 2020)	D) - 02 Feb 2020	
	Odds Ratio	Lower 95% CI	Upper 95% CI	Odds Ratio	Lower 95% CI	Upper 95% CI	S O Ogelds Ratio	Lower 95% CI	Upp CI
Female	0.83	0.69	0.99	0.92	0.80	1.06	e 0.77	0.66	0.90
BAME	1.27	0.89	1.81	1.36	1.04	1.79	0.97	0.72	
Age group (Ref = $60-64$)							•		
18-29	1.80	1.22	2.67	1.26	0.92	1.72	Download 1.68 1.14 1.36 1.22	1.18	
30-39	0.99	0.68	1.44	1.03	0.77	1.38	0a 1.14	0.82	
40-49	0.85	0.59	1.24	1.07	0.80	1.44	<u>a</u> 1.36	1.00	
50-59	1.20	0.84	1.70	0.99	0.74	1.33	1.22	0.89	
Visit date	1.04	1.04	1.04	1.00	1.00	1.00	1.01	1.01	
Autonomy	0.58	0.36	0.92	0.98	0.94	1.02	0.96	0.92	
Face covering or masks ($\operatorname{Ref} = \operatorname{not}$	ot wearing face	covering or m	ask)				njop		
Yes my face is already covered Yes at work/school/other	0.27	0.04	1.90	0.59	0.34	1.03	1.38	0.59	
situations only Yes usually both	0.30	0.05	1.71	0.50	0.31	0.82	http://bmjopen.bmj.com/ 0.58	0.33	
work/school/other	0.20	0.04	1.13	0.44	0.27	0.73	S 0.58 ≥	0.31	
Autonomy x Face covering/mask Autonomy x Yes my face is	s (Ref = No fac	e covering/ma	sk)				h April 23,		
Autonomy x Yes my face is already covered Autonomy x Yes at work/school/other situations	1.73	1.04	2.89	-	-	3	- 23, 2024	-	
only Autonomy x Yes usually both	1.63	1.02	2.61	-	-	-	2024 by guest. Protected 27.66	-	
work/school/other	1.75	1.09	2.80	-	-	-	rt	-	
Contact with COIVD-19 positive	people (Ref =	no contact)					rote		
0-14 days	14.01	11.30	17.38	15.03	12.35	18.28	če 27.66	21.02	
15-28 days	3.56	2.50	5.07	5.16	4.00	6.65	षु 7.10	5.40	

			BMJ	Open			mjope			
							bmjopen-2021-054200			
29-60 days	1.79	1.01	3.15	2.32	1.76	3.05	054200	1.93	1.41	
61-90 days	1.73	0.44	6.83	1.15	0.65	2.03	on	1.20	0.81	
91+ days	0.90	0.38	2.14	1.23	0.69	2.22	25 (1.15	0.75	
Household size	1.04	0.96	1.13	1.05	0.99	1.11	October	1.01	0.93	
Smoke	0.82	0.66	1.02	0.95	0.81	1.11		0.93	0.78	
Region (Ref = Northeast)							2021. Downloaded			
Northwest	1.79	1.18	2.70	1.46	0.99	2.16	1. D	0.97	0.64	
Yorks Humber	1.25	0.81	1.92	1.32	0.89	1.96	own	0.36	0.22	
East midlands	0.73	0.45	1.20	1.15	0.75	1.77	load	0.52	0.32	
West midlands	0.55	0.34	0.90	0.91	0.61	1.38	led f	0.76	0.49	
East	0.25	0.15	0.42	0.53	0.35	0.80	from	0.66	0.43	
London	0.55	0.35	0.87	0.85	0.58	1.26		1.36	0.92	
South East	0.35	0.22	0.56	0.70	0.47	1.06	http://bmjop	0.89	0.59	
South West	0.29	0.16	0.51	0.45	0.28	0.72		0.34	0.21	
Variance (Household) Residual intraclass correlation	6.01	4.99	7.03	5.21	4.43	5.99	en.bmj.com/ on	7.21	5.98	
(Household)	0.49	0.43	0.54	0.50	0.45	0.54	con	0.58	0.54	
Variance (Individuals) Residual intraclass correlation	3.04	2.16	3.92	2.03	1.34	2.72		1.94	1.16	
(Individuals)	0.73	0.70	0.76	0.69	0.65	0.72	April 2	0.74	0.70	
N	187453			142056				79500		
No. of household	54383 73262			57203			Ň	47594		
No. of participant				75682			-	60252		



			BI	MJ Open			bmjopen-2021-054200	
Fable S3. Descriptive statistics N	= 409, 009						21-05420	
1	All				Male		Feßale	
	mean	sd	min	max	mean	sd	mean	sd
COVID-19 positive	0.0118		0	1	0.0120		0.0217	
Female	0.5328		0	1	0.0000		1.00000	
BAME	0.0766		0	1	0.0763		0.0870	
Age at visit	44.6401	(11.5266)	20	64	44.5303	(11.5765)	44. 7 364	(11.4819
Age group							Doy	
18-29	0.1269		0	1	0.1266		0.1271	
30-39	0.2146		0	1	0.2212		0.288	
40-49	0.2650		0	1	0.2639		0.2 § 59	
50-59	0.2949		0	1	0.2859		0.3 ₫ 29	
60+	0.0986		0	1	0.1024		0.0953	
Autonomy	4.2061	(1.8174)	0	7	4.5345	(1.6413)	3.9981	(1.9129)
Face mask							Jop	
No face mask	0.0149		0	1	0.0163		$0.0\frac{1}{1}37$	
Yes my face is already covered Yes at work/school/other situations	0.0290		0	1	0.0281		0.0297	
only	0.4855		0	1	0.5054		0.4880	
Yes usually both work/school/other	0.4707		0	1	0.4502		0.4	
Number of test	6.9757	(1.9761)	1	10+	6.9541	(1.9721)	6.9946	(1.9794)
Household size	2.6550	(1.1957)	1	10+	2.7384	(1.2039)	2.5819	(1.1836)
Work outside home days	3.0201	(2.0517)	0	7	3.1415	(2.1295)	2.9836	(1.9749)
Contact with COVID-19 positive							0. 72 43	
No contact	0.7911		0	1	0.8102			
0-14 days	0.0834		0	1	0.0730		0.0925	
15-28 days	0.0384		0	1	0.0350		0.0 = 13	
29-60 days	0.0441		0	1	0.0402		0.0475	
61-90 days	0.0189		0	1	0.0179		0.0998	
91+ days	0.0242		0	1	0.0238		0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.00	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 25 of 30				BMJ Open		bmjopen-2021-054200 0.4912
1 2 3						2021-0542
4	Work social distancing					200
5	Easy to maintain 2m	0.4914	0	1	0.5602	
6 7	Relatively easy to maintain 2m Difficult to maintain 2m but can be	0.1621	0	1	0.1818	0.1 2 48 Q
8	1m	0.1362	0	1	0.1272	0.1940
9	Very difficult to be more than 1m	0.2103	0	1	0.1309	0.2599
10 11	Work location					021
12	Working from home	0.2417	0	1	0.2561	0.2 2 91
13	Working somewhere else(not your	10				OWN
14	home)	0.6186	0	1	0.5985	0.6862
15	Both(from home and somewhere else)	0.1397	0	1	0.1454	0 1 9 /18
16 17	Work travel method	0.1397		1	0.1454	
18		0.0252	0	1	0.0259	0.1940 0.2299 0.2299 0.2091 0.6862 0.1562 0.1562 0.1562 0.1562 0.1562 0.1562 0.1562 0.1562 0.1564 0.1662 0.1662 0.1664 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.2009 0.0000000000
19	Underground/metro/light rail/tram	0.0252				
20	Train	0.0383	0		0.0443	0.0331
21	Bus/minibus/coach	0.0266	0		0.0206	0.0 3 18
22 23	Motorbike/scooter or moped	0.0040	0		0.0071	0.0914
23	Car or van	0.6985	0	1	0.6995	0.69.77
25	Taxi/minicab	0.0038	0	1	0.0037	0.0040
26	Bicycle	0.0358	0	1	0.0470	0.0260
27	On foot	0.1355	0	1	0.1181	0.1508
28	Other method	0.0323	0	1	0.0339	0.0 208
29 30	Smoking	0.3007	0	1	0.3257	0.2788
31	Work direct with patients	0.2184	0	1	0.1501	0.2788 0.27883 9 0.0512
32	Occupation					1 by
33	Corporate managers and directors	0.0787	0	1	0.1101	0.0512
34	Other managers and proprietors	0.0371	0	1	0.0495	0.0263
35 36	Science research engineering and					Pro
37	technology professionals	0.0516	0	1	0.0842	0.0夏31
38	Health professionals	0.0640	0	1	0.0275	0.0 <u>9</u>60
39	Teaching and educational			_		by
40	professionals	0.1065	0	1	0.0665	0.18/16
41						0.09660 by 0.19916
42 43						f.

			BMJ Open		
Dusiness modia and public service					
Business media and public service professionals	0.0678	0	1	0.0796	
Science engineering and technology		Ŭ	-	0.0720	
associate professionals	0.0152	0	1	0.0203	
Health and social care associated	0.01=0	0		0.0007	
professionals	0.0178	0	1	0.0097	
Protective service occupations	0.0210	0	I	0.0312	
Culture media and sports occupations	0.0252	0	1	0.0266	
Business and public service associated professionals	0.0812	0	1	0.0891	
Administrative occupations	0.1023	0	1	0.0603	
Secretarial and related occupations	0.0257	0	1	0.0031	
Skilled agricultural and related trades	0.0080		1	0.0128	
Skilled metal electrical and electronic	0.0080	0	1	0.0128	
trades	0.0303	0	1	0.0634	
Skilled construction and building					
trades	0.0259	0		0.0537	
Textiles printing and other skilled trades	0.0097	0		0.0123	
Caring personal service occupations	0.0722	0	1	0.0125	
Leisure travel and related personal	0.0722	0	1	0.0188	
service occupations	0.0094	0	1	0.0051	
Sales occupation	0.0397	0	1	0.0263	
Customer service occupations	0.0142	0	1	0.0096	
Process plant and machine operatives	0.0149	0	1	0.0279	
Transport and mobile machine driver					
and operatives	0.0261	0	1	0.0516	
Elementary trades and related occupations	0.0044	0	1	0.0084	
Elementary administration and	0.0044	0	1	0.0084	
service occupations	0.0511	0	1	0.0527	
Region					
Northeast	0.0503	0	1	0.0483	
Northwest	0.1435	0	1	0.1422	

Page 27 of 30				BMJ Open		bmjope
1						bmjopen-2021-054222 0.1200 0.0975
2 3						054
4	Yorks Humber	0.1021	0	1	0.1019	0.1822
5	East midlands	0.0776	0	1	0.0776	
6	West midlands	0.0943	0	1	0.0960	0.0829
7	East	0.1241	0	1	0.1262	0.1823 0.1830
8 9	London	0.1743	0	1	0.1759	0.1830
10	South East	0.1474	0	1	0.1480	0.1869
11	South West	0.0863	0	1	0.0840	0.1g69 0.0g884
12	Ν	0.1474 0.0863 409,009			191,089	212920
13 14						vnlo
15						ade
16						d fr
17						m
18						http
19 20						://br
20						njop
22						Den
23						b m
24						8
25 26						n/ c
27						A A
28						prii
29						23,
30						202
31 32						<u>14</u> b
33						y gi
34						Jest
35						ד
36						otec
37 38						coted
39						l by
40						cop
41						vnloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.
42						
43 44		For peer review	only - http://bmj	open.bmj.co	m/site/about/guideli	nes.xhtml
44 45						
46						

Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohortreporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

acate the study's design with a commonly used term in the title or abstract	Number 1
	1
	1
vide in the abstract an informative and balanced summary of what done and what was found	2
lain the scientific background and rationale for the investigation ng reported	3
e specific objectives, including any prespecified hypotheses	3
	3-5
	ent key elements of study design early in the paper

Page 29 of 30

BMJ Open

1 2 3	Setting	<u>#5</u>	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3-5
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	Eligibility criteria	<u>#6a</u>	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	3-5
	Eligibility criteria	<u>#6b</u>	For matched studies, give matching criteria and number of exposed and unexposed	n/a
	Variables	<u>#7</u>	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	3-5
	Data sources / measurement	<u>#8</u>	For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for for exposed and unexposed groups if applicable.	3-5
26 27	Bias	<u>#9</u>	Describe any efforts to address potential sources of bias	3-5
28 29	Study size	<u>#10</u>	Explain how the study size was arrived at	3-5
30 31 32 33	Quantitative variables	<u>#11</u>	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	3-5
34 35 36 37	Statistical methods	<u>#12a</u>	Describe all statistical methods, including those used to control for confounding	
38 39	3-5			
40 41 42 43	Statistical methods	<u>#12b</u>	Describe any methods used to examine subgroups and interactions	3-5
44 45 46 47	Statistical methods	<u>#12c</u>	Explain how missing data were addressed	3-5
47 48 49 50	Statistical methods	<u>#12d</u>	If applicable, explain how loss to follow-up was addressed	n/a
51 52 53 54 55	Statistical methods	<u>#12e</u>	Describe any sensitivity analyses	
55 56 57	3-5			•
58 59 60	Results	For p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Participants	<u>#13a</u>	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.	5-6
Participants	<u>#13b</u>	Give reasons for non-participation at each stage	n/a
Participants	<u>#13c</u>	Consider use of a flow diagram	
n/a			
Descriptive data	<u>#14a</u>	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	5-6
Descriptive data	<u>#14b</u>	Indicate number of participants with missing data for each variable of interest	
n/a			
Descriptive data	<u>#14c</u>	Summarise follow-up time (eg, average and total amount)	
n/a			
Outcome data	<u>#15</u>	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.	
n/a			
Main results	<u>#16a</u>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	5-6
Main results	<u>#16b</u>	Report category boundaries when continuous variables were categorized	5-6
Main results	<u>#16c</u>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
n/a			
	For p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

rage	510150		open	
1 2 3	Other analyses	<u>#17</u>	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	5-6
4 5	Discussion			
6 7 8	Key results	<u>#18</u>	Summarise key results with reference to study objectives	6-7
9 10 11 12 13	Limitations	<u>#19</u>	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	6-7
14 15 16 17 18	Interpretation	<u>#20</u>	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	6-7
19 20 21	Generalisability	<u>#21</u>	Discuss the generalisability (external validity) of the study results	6-7
22 23	Other			
24 25	Information			
26 27 28 29 30	Funding	<u>#22</u>	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1
31 32	The STROBE chec	klist is c	listributed under the terms of the Creative Commons Attribution License Co	C-BY.
33 34	This checklist was	complet	ed on 04. June 2021 using https://www.goodreports.org/, a tool made by the	2
35 36	EQUATOR Netwo	<u>rk</u> in col	laboration with <u>Penelope.ai</u>	
37 38 39 40 41 42 43 44				
45 46 47 48 49 50				
51 52 53 54 55 56 57 58 59		_		
60		Forp	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

Factors affecting adherence to non-pharmaceutical interventions for COVID-19 infections in the first year of the pandemic in the UK: Analysis of the repeated household Covid Infection Study (CIS)

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-054200.R1
Article Type:	Original research
Date Submitted by the Author:	02-Sep-2021
Complete List of Authors:	Ding, Xuejie; University of Oxford Brazel, David M.; University of Oxford Mills, Melinda; University of Oxford,
Primary Subject Heading :	Health policy
Secondary Subject Heading:	Epidemiology, Health policy, Public health, Sociology
Keywords:	COVID-19, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Public health < INFECTIOUS DISEASES





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

Factors affecting adherence to non-pharmaceutical interventions for COVID-19 infections in the first year of the pandemic in the UK: Analysis of the repeated household Covid Infection Study (CIS) Xuejie Ding,^{a,†} David M. Brazel,^a and Melinda C. Mills^{a,†}

^a Leverhulme Centre for Demographic Science and Nuffield College, University of Oxford,

UK

⁺ corresponding authors: <u>xuejie.ding@sociology.ox.ac.uk</u> and <u>melinda.mills@nuffield.ox.ac.uk</u>

Funding

Funding is provided by the Leverhulme Trust (LCDS) and ERC Advanced Grant (835079) to MCM. The funders had no role in study design, data collection, analysis, interpretation, or writing.

Contributions

MCM, XD, DMB designed the study and MCM wrote the report, to which all authors contributed. MCM, XD and DMB designed the models. XD and DMB prepared the data and ran the models. MCM designed the time-varying graphic. All authors read and approved the final article.

Declaration of interests

MCM is a member of the UK Scientific Advisory Group for Emergencies sub-groups SPI-B (behavioural insights), ethnicity and Vaccines Science Coordination Group and member of the Royal Society's SET-C (Science in Emergencies Tasking – COVID) group, all which respond to requests from government departments and the Government Office for Science.

Data Sharing

This work contains statistical data from Office of National Statistics (ONS) which is Crown Copyright. The use of the ONS statistical data in this work does not imply the endorsement of the ONS in relation to the interpretation or analysis of the statistical data. This work uses research datasets which may not exactly reproduce National Statistics aggregates. The Covid Infection Study (CIS) data are available via a formal request to the ONS Secure Research Service for accredited researchers.

Acknowledgements

This work was supported by the Leverhulme Trust, Leverhulme Centre for Demographic Science (Grant number N/A) and ERC Advanced Grant (835079). We thank C. Rahal for his assistance in the time-varying graphic.

Number of figures: 4

Word count: 3,287

Competing interest statement:

The authors declare no competing interest.

ABSTRACT

Objective

Non-pharmaceutical interventions (NPIs), including wearing face covering/masks, social distancing and working-from-home, have been introduced to control SARS-CoV-2 infections. We provide individual-level empirical evidence of whether adherence reduces infections.

Setting and participants

The Covid-19 Infection Study (CIS) was used from 10 May 2020 to 02 February 2021 with 409,009 COVID-19 nose and throat swab tests nested in 72,866 households for 100,138 individuals in the labour force aged 18-64.

Analysis

Odds ratios (ORs) for a positive COVID-19 test were calculated using multilevel logistic regression models, stratified by sex and time, by an index of autonomy to abide to NPIs, adjusted for various socioeconomic and behavioural covariates.

Results

Inability to comply with NPIs predicted higher infections when individuals reported not wearing a face-covering outside. The main effect for inability to comply was OR: 0.79 (95% CI 0.67–0.92), for wearing face-covering/masks was OR: 0.29 (95% CI 0.15–0.56), and the interaction term being OR: 1.25 (95% CI 1.07–1.46). The youngest age groups had a significantly higher risk of infection (OR: 1.52, 95% CI 1.28–1.82) as did women in larger households (OR: 1.06, 95% CI 1.02–1.06). Effects varied over time with autonomy to follow NPIs only significant in the pre-second lockdown May–November 2020 period. Wearing a face-covering outside was a significant predictor of a lower chance of infection before mid–December 2020 when a stricter second lockdown was implemented (OR: 0.44, 95% CI 0.27–0.73).

Conclusion

The protective effect of wearing a face-covering/mask was the strongest for those who were the most unable to comply with NPIs. Higher infection rates were in younger groups and women in large households. Wearing a face-covering or mask outside the home consistently and significantly predicted lower infection before the 2020 Christmas period and amongst women.

Strengths and limitations of this study

- The first large-scale study that links individual and household level adherence to NPIs plus their autonomy to adhere with actual measured infections.
- This representative population-based study went beyond the use of aggregated population-wide case data or individual self-reporting of SARS-CoV-2 to use individual throat and swab SARS-CoV-2 positivity testing.
- Our measure of infection captured those who might be asymptomatic or whose infections are relatively mild.
- Although the dataset is the most representative to date, some groups such as ethnic minorities (termed BAME in the UK) are still underrepresented in the sample.
- Participation in the study is voluntary and thus self-selection bias may affect the results.

INTRODUCTION

 Although most countries have introduced non-pharmaceutical interventions (NPIs) to lower the spread of infectious diseases such as SARS-CoV-2, there is limited empirical research on the relationship of adherence to NPIs with infections or how an individuals' autonomy or ability to follow NPI measures relates to infections,[1]. To form evidence-based health policy, it is crucial to have empirical evidence that tests whether the adherence to NPIs is effective in reducing infection. The lack of compliance to NPIs has been generally positioned as an attitude or choice [2], but it may be related to the inability to follow measures and thus exacerbate existing health inequalities. This includes employment that does not accommodate working at home, the necessity to take public transport, or being in workplaces or households where recommended social distancing is not possible.

Due to data limitations, existing research examining the effects of NPIs on COVID-19 related outcomes has almost exclusively used aggregated data to model the correlation between the timing of various national, state or regional level NPIs with COVID-19 case rates [1,3-6]. These types of studies risk producing an ecological fallacy, since the interpretation of statistical data about individuals are deduced from an inference for the group to which those individuals belong [1]. In the early stages of the pandemic in 2020, some simulations also estimated the potential ebb and flow of infections in relation to the introduction of various NPIs and how this might impact healthcare demands [7]. There have been various systematic reviews and meta-analyses, some with mixed results, but generally demonstrating the protective nature of NPIs [8,9]. Other studies examining the effectiveness of face coverings and masks have been largely carried out in health settings examining N95 or surgical masks, with critiques that findings cannot be transferred to community settings or do not properly control for confounders [9].

Although a handful of individual-level studies more directly examined the relationship between individual adherence to NPIs and individual-level case data of infections, they were carried out in the early stages of the pandemic, had small samples (1,000,[10] or 1,500 cases [11]), and used very general NPI measures. A previous review concluded that although many studies have assessed NPIs, few were able directly examine or quantify their impact [12]. We aimed to measure the association between COVID-19 infections and the autonomy to follow NPIs, key sociodemographic factors, and changes over time, using individual- and household-level data in a large nationally representative sample in the UK collected over almost one year from May 2020 to February 2021.

METHODS

Study design and participants

The Covid Infection Study (CIS) is one of the largest regular surveys of coronavirus infections and antibodies,[13]. The CIS has been used to examine multiple aspects of the pandemic and to monitor community prevalence of SARS-CoV-2 infection,[14]. Samples, demographic information and a short questionnaire are collected from individuals aged 2 and older living in private households in England, randomly selected from address lists and the Office of National Statistics (ONS) surveys. It is a repeated household survey with additional serial sampling and longitudinal follow-up. Data includes a questionnaire and nose and throat swabs. If multiple household members agreed to participate, a home visit was made to collect information. Following the first visit, participants who agree, are visited every week for the first five weeks and then receive optional monthly visits. All study protocol and questionnaires are available online (https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey).

A positive COVID-19 test was determined from nose and throat swabs using the TaqPath RT-PCR COVID-19 kit (Thermo Fisher Scientific, Waltham, MA, USA), analysed using UgenTec Fast Finder 3.300.5 (TaqMan 2019-nCoV assay kit V2 UK NHS ABI 7500 v2.1; UgenTec, Hasselt, Belgium), described in detail in the sources listed above. Tests are considered positive when at least one gene is present – N, ORF1ab, or both – but could be accompanied by the gene for S protein (detection of S protein alone is not considered reliable) [14]. For the analyses in this study, the Covid-19 Infection Study (CIS) from 10 May 2020 to 02 February 2021 was used with 409,009 valid COVID-19 tests from nose and throat swabs nested in 72,866 households for 100,138 individuals in the labour force aged 18-64 years.

Measurement of autonomy

Autonomy to adhere to NPIs is measured by summing conditions that might limit their ability to comply. Each question was asked at every visit to each participant. We assigned points to these conditions which were then summed into one index that measures autonomy. The measures are that the respondent reports that they: (1) work outside the home at least one day per week (1 point), (2) find it 'easy to maintain 2 metres' distance in workplace (0 points), (3) find it 'relatively easy to maintain 2 metres' distance in the workplace (1 point), (4) find it 'difficult to maintain 2 metres, but can be 1 metre' in the workplace (2 points), (5) 'very difficult to be more than 1 metre away' in the workplace (3 points), (6) are at a main working location that is 'somewhere else (not your home)' (1 point), (7) find it common to go to and from work/school by bus, coach or minibus (1 point); and, (8) engage in work that involves direct contact with patients, clients, residents, service users or customers on a day-to-day basis (1 point). We included transportation by bus, coach or minibus and reduced the reliability of our autonomy index.

The autonomy index passed the Cronbach's alpha test with the reliability coefficient of 0.73. Exact questions used for the construction of the measurement of autonomy can be found in the supplementary materials (Table S1). Spearman correlation amongst each item and the final autonomy score is documented in the supplementary materials (Table S2 & Figure S1).

To interpret the index we consider an example. A person who reports working outside home for 5 days a week (+1), in a job where it is difficult to maintain 2 metre distancing, but can maintain 1 metre (+2) and whose main work location is not home (+1) and does not take public transportation of a bus (0), but works directly with people (+1) will score 5 in autonomy. After summing the scores, we reverse coded the autonomy variable so that a lower score indicates low autonomy (i.e., more situations that limit the individuals' ability to comply) and a higher autonomy score indicates a higher ability to comply with NPIs. The range for the autonomy score is from 0-7, with the person described in the previous example scored as 2 given reverse coding.

Statistical analysis

We estimated the likelihood of testing positive for SARS-CoV-2 from nose and throat swabs using three-level multivariate multilevel logistic regression models, also stratified by sex and time period. The outcome is a positive SARS-CoV-2 test, with the main predictors of sex, Black, Asian or minority ethnicity (BAME), age group, visit date, household size, smoking

status, region, occupation, days since contact with any COVID-19 positive person, compliance with wearing a face covering or mask and autonomy to comply with NPIs.

Mixed-level logistic regression models were estimated with COVID-19 tests (level 1) nested within individuals (level 2) nested within households (level 3) with the outcome variable of COVID-19 positive infections. The main model estimates sex, ethnicity, age group, reporting to wear a face covering or mask, our autonomy to comply index and additional control variables. Model 2 adds an interaction term between autonomy to adhere and wearing a face covering or mask. Model 3 is the same as model 2 but only includes females. Model 4 is the same as the main model but only includes males. We estimated sex-specific models since when we added the interaction term for men only in the model, the interaction terms were not significant, the model fit did not increase, and the main effect also disappeared. We therefore consider the interaction terms in the male model as an unnecessary control and only reported the main models for men. Next, we stratified the models by three periods that broadly reflect the various phases of restrictions in the UK of: (1) 10 May - November 04 (pre-lockdown 2), (2) 05 November to December 19 (lockdown 2 'light version'), and (3) 20 December to Feb 02 (Lockdown 2 stricter) (See Figure 1). These periods follow the general guidelines, which varied somewhat across the four nations of England, Scotland, Wales and Northern Ireland. For the first periods, we were able to fit the model with the interaction term, and for the second and third period we fit the main model without the interaction term for the same reason mentioned above in relation to sex. Occupation was not included in the models by time periods due to the small sample sizes in each category.

Patient and public involvement

Patients and the public were not involved in the development of research questions, design of the study, recruitment, and conduct of the study, or dissemination of the study results.

RESULTS

The autonomy score ranges from 0 to 7 (Mean = 4.21, SD = 1.82), with a higher score indicating more autonomy. The distribution of the autonomy score for the entire sample and by sub-groups is presented in Figure 2. The autonomy score follows a normal distribution. Men, and particularly men above 40 years of age, report more autonomy than women and younger counterparts.

We find that the level of autonomy to adhere to NPIs does not predict COVID-19 infection alone, but rather the risk of infection is diminished when individuals wear facecovering/masks (Figure 3, or Table S3). For example, the main effect model in Figure 3 and Model 1 in Table S3 shows that with one higher score in autonomy (i.e., one more condition that limited the respondents' ability to comply to NPIs), there is a 3% lower likelihood of testing positive for SARS-CoV-2 (OR: 0.97; 95% CI 0.95 to 0.99). The coefficient is however marginally statistically significant, and the magnitude is small.

In Figure 2 (also see supplementary materials, Table S3, Model 2), we add interaction terms between autonomy and compliance of wearing face covering/mask. We found that the protective effect of wearing a face covering/mask is stronger when autonomy is low. We visualise this interaction effect based on model 3 in Figure 4. The interaction effect is the most pronounced amongst females.

The youngest 18-29 year old age groups have a significantly higher odds of infection (OR 1.17; 95% CI 1.00–1.37), with living in a larger household only related to a significantly

higher odds of infection for women (OR: 1.04; 95%CI 1.02–1.06). Male smokers had a significantly lower risk (OR: 0.84; 95%CI 0.74–0.94]). This is in line with a recent review of 17 studies that also found that current smokers had a reduced risk of testing positive for COVID-19 [15].

To test whether our core predictors change in relation to key policy restrictions put in place to restrict infections, hospitalisation and deaths (Figure 1, or Table S2), we divided the analysis into three policy periods (available in our data) of: (1) 10 May 2020 – 04 November 2020 (first lockdown to pre-second lockdown), (2) 05 November – 19 December (second lockdown and pre-Christmas period of 'lockdown light'); and, (3) 20 December – 02 February (stricter second lockdown with schools closed and introduction of Tier 4). Figure 1 illustrates the clear time-lag between infections leading to deaths, with growing evidence that this link is disrupted by vaccinations as time elapses. Black, Asian and minority ethnic groups were more likely to be infected, especially during the second lockdown (05 Nov-19 December) (OR: 1.36; 95%CI 1.04–1.79).

Effects varied over the year with autonomy to follow NPIs only significant in the pre-Second lockdown period (May–November 2020). Wearing a face covering or mask outdoors was a significant predictor of a lower chance of infection before 19 December 2020 (OR: 0.44; 95%CI 0.27–0.73) when a stricter second lockdown was implemented. One possible explanation is that the percentage of people not wearing face covering/masks was low and declined from 2% to 1% from May 2020 to Feb 2021. The variable may also be capturing both the social environment (i.e., wearing a face covering may be influenced by the level of individuals wearing masks around you) and correlated health behaviours (i.e., those who wear face coverings are more cautious in other ways).

In the full models, the random effects variance estimates were larger at the household level than at the individual level OR: 3.34 (95%CI 3.05–3.63) versus OR: 1.02 (95% CI 0.78–1.26), suggesting that more unexplained variation in infection risk exists at the household level. This difference was smaller or non-existent in the sex-stratified models, with the residual intraclass coefficients also reflecting a loss of household information.

DISCUSSION

Using multivariate multilevel logistic regression models, we examined the relationship between individual adherence to NPIs and COVID-19 infection, controlling for key sociodemographic, behavioural and time-related policy changes. We found that an individuals' autonomy to comply with NPIs predicts higher infections when individuals do not engage in other protective measures of wearing a face covering or mask outside their home. Our results suggest that engaging in protective behaviours such as wearing face coverings can reduce the unequal effects of exposure to COVID-19, noted in previous literature reviews [9]. Our findings emphasise the need to move to more complex models beyond comparing aggregated percentages of general population compliance to a more nuanced understanding that stratifies groups in meaningful ways to develop tailored health policy interventions and communications. We found that women living in larger households had a significantly higher risk of infection, reflecting more domestic and care duties and time in the household, but also multiple individuals leaving and returning the home from diverse environments.

The 18-29 year old age group had a significantly higher risk of infection, suggesting that this is an important group to consider given that many countries have been engaging in age-

related vaccine roll-outs. Effects varied over the year with autonomy to follow NPIs only significant in the pre-Second lockdown period (May- November 2020). This was a period where initially many UK governments were reluctant to introduce certain policy interventions, such as the relatively late introduction of face-coverings for the general public in late June or July 2020, first in public transport only [2].

Wearing a face covering or mask outside the home was a significant predictor of a lower chance of infection before 19 December 2020 when a stricter second lockdown was implemented. BAME groups are more likely to be infected, especially during the second lockdown (05 November–19 December). We note, however, that although we see some period variation, given the overlap in CIs and the fact that we are not strictly testing a difference between the coefficients in our model, they are not statistically different.

A strength of our study is that it is to our knowledge the first large-scale study that links the reporting of individual and household level adherence to NPIs and their ability or challenges to adhere with actual measured infections. This representative population-based study went beyond the self-reporting of SARS-CoV-2 to use throat and swab SARS-CoV-2 positivity testing opposed to population-wide case data, which is subject to significant selection bias. This is also an advantage over other measures such as hospitalisation or death, which only pick up the most severe cases. By measuring infections in this manner, we are also able capture those who might be asymptomatic or whose infections are relatively mild. Given the multilevel design based on a sample that was designed to be a random sample of households stratified by gender and time period, we also avoid problems in interpretation over this period due to changes in testing practice. Another advantage is that we have longitudinal, regularly collected data over this period which allows us to examine changes in behaviour over time.

Our study is also subject to several limitations. Although the dataset is the most representative to date, some groups such as ethnic minorities (termed BAME in the UK) remain underrepresented in the sample. Whereas we have 7% BAME, amongst the UK population, around 14% are from a minority ethnic background. Therefore, our estimates may not reflect the full range of the population. Future work may incorporate our individual- and household- level approach with the aggregate level approach [16, 17] together to analyse population scale NPIs and risk attitudes/behaviours. The number of tests in the lockdown 2 'stricter version' period is much smaller, meaning that we may not have the power to detect some effects. Participation in the study is voluntary and thus self-selection bias may affect the results. In addition, as others have noted, we are unable to determine the sensitivity and specificity of the PCR test, but it is likely close to 100% [18]. Finally, the mixed logit models assume linearity between the continuous predictors and the log odds of the outcome of interest. Violating linearity can affect prediction and inference. Since most of our predictors are categorical/binary and we only include three continuous predictors – visit date, autonomy, and household size - in the analyses, it is unlikely that the linearity assumption is severely violated. The plot of the logit for continuous predictors (Supplementary materials, Figure S2) also alleviates the concern.

CONCLUSION

Many countries introduced multiple non-pharmaceutical interventions (NPIs) to control COVID-19 infections, hospitalization and deaths and continue to implement or re-introduce them during spikes in infections even during vaccine roll-out. There have been limited empirical studies using individual-level data to examine how individual adherence to NPIs

predicts infections by sociodemographic factors, individual autonomy to abide by NPIs and how these relationships change over time in relation to different restrictions.

We move beyond aggregated figures showing macro correlations of NPI policy stringency with national-level COVID-19 outcomes, to produce individual- and household-level models that properly control for confounders, key sociodemographic and behavioural factors and changes in policy interventions over time. Using the Covid Infection Study (CIS) in the UK with almost one year of data from 10 May 2020 to 02 February 2021, with 409,009 valid COVID-19 tests nested in 72,866 households for 100,138 individuals aged 18-64 years, we estimate multivariate multilevel logistic regression models, stratified by sex and time-period. We create a novel index measuring individual autonomy to abide by NPIs index (i.e., ability to work at home and number of days at home, ability to maintain physical distancing at work, travel to work requires public transport, or work involves direct contact).

Although autonomy or inability to abide by NPIs is a significant predictor of higher infection rates amongst certain groups, it does not predict infection alone. Wearing a face covering or mask outside the home can reduce the unequal effects of exposure to COVID-19 due to individual and employment circumstances. Autonomy to follow NPIs was only a significant predictor of infection risk from May to November 2020 but those who reported wearing a face covering or mask outdoors significantly had lower rates of infection for individuals with lower level of autonomy between 10 May to 04 November and for all people between 05 November to 19 December 2020.

The results we present here summarise key parts of the analyses we presented to senior decision makers in the UK over February–March 2021, in a context with rapidly evolving information, vaccine deployment and other relevant policies. As the pandemic evolves, new variants of concern emerge and vaccines are rolled-out across the world, experts, politicians and civil servants will continue to make difficult decisions on lifting or re-instating NPIs. This study provides novel and nuanced empirical evidence of the relationship of autonomy to follow NPIs with infection, how this varies and where support or public communication could be directed.

Ethical Approval Statement. Participants provided informed consent when they took part in the CIS study. More information can be found here:

https://www.ons.gov.uk/surveys/informationforhouseholdsandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdandindividuals/householdan

References

Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584: 257-61. Bish A, Michie S. Demographic and attitudinal determinants of protective behaviours during a pandemic: A review. Br J Health Psychol 2010; 15: 797–824. Bo Y, Guo C, Lin C, et al. Effectiveness of non-pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13 April 2020. Int J Infect Dis 2021; **102**: 247–53. Islam N, Sharp SJ, Chowell G, et al. Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. BMJ 2020; : m2743. Haug N, Geyrhofer L, Londei A, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav 2020; 4: 1303-12. White ER, Hébert-Dufresne L. State-level variation of initial COVID-19 dynamics in the United States. PLoS One 2020; 15: e0240648.

- 7 Davies NG, Kucharski AJ, Eggo RM, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Heal 2020; 5: e375–85.
- 8 Chu DK, Akl EA, Duda S, *et al.* Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* 2020; published online June. DOI:10.1016/S0140-6736(20)31142-9.
- 9 Mills MC, Akimova ET, Rahal C. Face masks and coverings for the general public: Behavioural knowledge, effectiveness of cloth coverings and public messaging. 2020 https://royalsociety.org/-/media/policy/projects/set-c/set-c-facemasks.pdf?la=en-GB&hash=A22A87CB28F7D6AD9BD93BBCBFC2BB24.
- 10 Sun K, Wang W, Gao L, *et al.* Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. *Science (80-)* 2021; **371**: eabe2424.
- 11 Jefferies S, French N, Gilkison C, *et al.* COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. *Lancet Public Heal* 2020; **5**: e612–23.
- 12 Imai N, Gaythorpe KAM, Abbott S, *et al.* Adoption and impact of non-pharmaceutical interventions for COVID-19. *Wellcome Open Res* 2020; **5**: 59.
- 13 ONS. COVID-19 Infection Survey. ONS Rep. 2020. https://www.ons.gov.uk/surveys/informationforhouseholdsandindividuals/househol dandindividualsurveys/covid19infectionsurvey (accessed Feb 14, 2021).
- 14 Pouwels KB, House T, Pritchard E, *et al.* Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. *Lancet Public Heal* 2021; **6**: e30–8.
- 15 Simons, D., Shahab, L., Brown, J., & Perski, O. (2020). The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction.
- 16 Chan, L. Y. H., Yuan, B., & Convertino, M. (2021). COVID-19 non-pharmaceutical intervention portfolio effectiveness and risk communication predominance. Scientific reports, 11(1), 1-17.
- 17 Haug, N., Geyrhofer, L., Londei, A., Dervic, E., Desvars-Larrive, A., Loreto, V., ... & Klimek, P. (2020). Ranking the effectiveness of worldwide COVID-19 government interventions. Nature human behaviour, 4(12), 1303-1312.

1 2 3 4 5 6 7	18	Cameron-Blake E, et al. Variation in the response to COVID-19 across the four nations of the United Kingdom. 2020 https://www.bsg.ox.ac.uk/sites/default/files/2020-10/BSG-WP-2020-035-v1_0.pdf.
8 9 10 11 12 13 14		
15 16 17 18 19 20		
21 22 23 24 25 26 27		
28 29 30 31 32 33 34		
35 36 37 38 39 40 41		
42 43 44 45 46 47 48		
49 50 51 52 53 54 55		
55 56 57 58 59 60		

¢

bmjopen-2021-05

Figure 1. Timeline of key restrictions in England by COVID-19 cases (left) and deaths (right), January 01 2020 to March 08 2021.

Note: JCVI (Joint Committee on Vaccination and Immunisation); AZ (Astra Zeneca). Graph produced by authors using policy data for England, ¹/₂₁₈ and official UK Government data on COVID-19 cases and deaths, ¹⁹ smoothed into 14 day rolling means. Deaths are in red (read from right axis) and cases in blue (read from left axis) with magnitudes representing smoothed 14 day Let was some varia. rolling means and not cumulative figures. The restrictions shown here are for England and we note there was some variation in the detail of some policies and slight variation in timing in Scotland, England, Wales and Northern Ireland, ober 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright

Page 13 of 39

Figure 2. Distribution of the measure of autonomy within the sample and by sample subgroups.

ru 23, 2024 by gt


bmjopen-2021-054200 on 25 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright


BMJ Open Figure 3. Three-level logistic regression models of COVID-19 positive tests, 10 May 2020 – 02 February 2029 by key fixed-effect predictors and interaction effects (see supplementary materials for full tables) ONS Covid Infection Study interaction effects (see supplementary materials for full tables), ONS Covid Infection Study. on 25 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright

to 2024 by gu

Page 15 of 39	BMJ Open	bmjope	
1 2 3 4 5 6 7 8	BMJ Open Figure 4. Association between infection and autonomy by level of compliance to wearing face-covering/ma	an-2021-0542200 on 25 Octob	(estimates from Model 3).
9 10 11 12 13 14 15 16 17 18		er 2021. Downloaded from h	
19 20 21 22 23 24 25 26		2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.	
27 28 29 30 31 32 33 34 35		April 23, 2024 by guest. F	
36 37 38 39 40 41 42 43		^o rotected by copyright.	
43 44 45	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

BMJ Open: first published as 10.1136/bmjopen-2021-054200 on 25 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.







Note: JCVI (Joint Committee on Vaccination and Immunisation); AZ (Astra Zeneca). Graph produced by authors using policy data for England,17,18 and official UK Government data on COVID-19 cases and deaths,19 smoothed into 14 day rolling means. Deaths are in red (read from right axis) and cases in blue (read from left axis) with magnitudes representing smoothed 14 day rolling means and not cumulative figures. The restrictions shown here are for England and we note there was some variation in the detail of some policies and slight variation in timing in Scotland, England, Wales and Northern Ireland.

246x128mm (220 x 220 DPI)

œ

9

0

18-29

Age

30-39

40-49


Female

50-59

Male

60-69

Panel B. Box plot of autonomy by age and sex






Figure 3. Three-level logistic regression models of COVID-19 positive tests, 10 May 2020 – 02 February 2021 by key fixed-effect predictorsand interaction effects (see supplementary materials for full tables), ONS Covid Infection Study.

184x147mm (144 x 144 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml




Figure 4. Association between infection and autonomy by level of compliance to wearing facecovering/masks (estimates from Model 3).

BMJ Open: first published as 10.1136/bmjopen-2021-054200 on 25 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.

208x145mm (300 x 300 DPI)

BMJ Open Factors affecting adherence to non-pharmaceutical interventions for COVID-19 infections in the first year of the pandemic in the UK: Analysis of the repeated household Covid Infection Study (CIS) **Supplementary Materials**)ctober


1. Construction of the Measurement of Autonomy

 Autonomy to adhere to NPIs is measured via the sum of several situations that might limit the respondents' ability to comply. Each question was asked repeatedly at each visit to every participant. We assigned points to these situations and summed the points into one index measuring the autonomy. The exact questions we used and the points assigned are listed in Table S1.

Exact Question	m and score assignment used to construct the measurement of autonon \vec{ay} . Response Item and score assigned in the bracket \vec{a}
On average, on how many days of	
the week are you currently	
working somewhere else (not at	
your home, defined as the same	
grounds or building as your	5) 4 (1')
home), or currently attending, in	6) 5 (1')
person, your place of education,	
school, nursery, pre-school or	$\begin{array}{c} 1) & 0 & (0) \\ 2) & 1 & (1') \\ 3) & 2 & (1') \\ 4) & 3 & (1') \\ 5) & 4 & (1') \\ 6) & 5 & (1') \\ 7) & 6 & (1') \\ 8) & 7 & (1') \end{array}$
childminder? (select one)	Q
2 On average how easy is it to	1) Easy to maintain 2m, it is not a problem to stay this far away from othe people $(0')$
maintain 1-2m between yourself	2) Relatively easy to maintain 2m, most of the time I can be 2m away from other people (1')
and other people at your place of	3) Difficult to maintain 2m, but I can usually be at least 1m from other people $(2')$
work/full-time	4) Very difficult to be more than 1m away, as my work means I am in close contact with others on a regular
education/school/nursery, etc?	basis (3')
(select one)	gu e
3 Currently, where are you mainly	1) Working from home (in the same grounds or building as your home) $(0^{\frac{1}{2}})$
working now? (select one)	2) Working somewhere else (not at your home) (1')
	 3) Both (working from home and working somewhere else) (0')
4 How do you mainly get to and	1) Underground, metro, light rail, tram (0')
from work/nursery/school? (select	2) Train (0') 8

Page 21 of 39		BMJ Open	bmjope
1 2			n-2021-05
3 4 5 6 7 8 9 10	one: if use multiple modes, choose the longest part of your journey in time)	 3) Bus, minibus, coach (1') 4) Motorbike, scooter or moped (0') 5) Car or van (0') 6) Taxi/minicab (0') 7) Bicycle (0') 8) On foot (0') 9) Other method (0') 	bmjopen-2021-054200 on 25 October 2021. Downloaded from
11 12 13 14 15 16 17	5 Does your current role primarily involve direct contact, in person, with patients/clients/residents/service users/customers on a day-to-day basis? (Please answer 'no' if primarily office-based)	1) Yes (1') 2) No (0')	-
19 20 21 22	underground, tram or motorbike, scoo autonomy index.	bus, coach or minibus only since sensitivity analyses that included other oter, or car all showed a reverse correlation with other autonomy items s are available online (<u>https://www.ndm.ox.ac.uk/covid-19/covid-19-int</u>	and reduced the reliability of our
23 24 25 26 27			bmj.com/ on Ar
28 29 30 31 32			bmj.com/ on April 23, 2024 by gu
33 34 35 36 37			
38 39 40 41			əst. Protected by copyright.
42 43 44 45		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	1.

46



Page	23	of	39
------	----	----	----

BMJ Open

bmjopen-2021-0

Lower 95% CI 0.81 1.00 1.28 0.94 0.98 0.97 1.02 0.95 t wearing f 0.72 0.59	Upper 95% CI 0.99 1.37 1.82 1.33 1.40 1.33 1.02 0.99 face coverin 1.41	Odds Ratio 0.90 1.17 1.52 1.12 1.17 1.14 1.02 0.79 ng or mask 0.37	Lower 95% CI 0.81 1.00 1.28 0.94 0.98 0.97 1.02 0.67) 0.16	Upper 95% CI 0.99 1.37 1.82 1.33 1.40 1.33 1.02 0.92 0.82	Odds Ratio - 1.17 1.58 1.08 1.21 1.12 1.02 0.70 0.23	Lower 95% CI - 0.95 1.23 0.86 0.96 0.88 1.02 0.55 0.09	Upper 95% CI - 1.46 2.04 1.37 1.53 1.41 1.02 0.88 0.64	Odds Ratio Podds Ratio Podds Ratio Podds 1.23 1.23 1.23 1.23 1.23 1.40 1.40 1.15 1.08 1.19 1.02 1.02 1.02 0.97	Lower 95% CI - 0.99 1.09 0.91 0.86 0.94 1.02 0.93 0.64	Upper 95% Cl 1.5: 1.8 1.4 1.3 1.5 1.0 1.0 1.0
1.00 1.28 0.94 0.98 0.97 1.02 0.95 t wearing f	1.37 1.82 1.33 1.40 1.33 1.02 0.99 face coverin	1.17 1.52 1.12 1.17 1.14 1.02 0.79 mg or mask	1.00 1.28 0.94 0.98 0.97 1.02 0.67	1.37 1.82 1.33 1.40 1.33 1.02 0.92	1.17 1.58 1.08 1.21 1.12 1.02 0.70	0.95 1.23 0.86 0.96 0.88 1.02 0.55	2.04 1.37 1.53 1.41 1.02 0.88	22 1.23 Download 1.15 def 1.08 from 1.19	0.99 1.09 0.91 0.86 0.94 1.02 0.93	1.8 1.4 1.3 1.5 1.0 1.0
1.28 0.94 0.98 0.97 1.02 0.95 t wearing f	1.82 1.33 1.40 1.33 1.02 0.99 face coverin	1.52 1.12 1.17 1.14 1.02 0.79 mg or mask	1.28 0.94 0.98 0.97 1.02 0.67	1.82 1.33 1.40 1.33 1.02 0.92	1.58 1.08 1.21 1.12 1.02 0.70	1.23 0.86 0.96 0.88 1.02 0.55	2.04 1.37 1.53 1.41 1.02 0.88	. Download 1.15 ded from 1.19 htt 1.02	1.09 0.91 0.86 0.94 1.02 0.93	1.8 1.4 1.3 1.5 1.0 1.0
0.94 0.98 0.97 1.02 0.95 t wearing f	1.33 1.40 1.33 1.02 0.99 face coverin	1.12 1.17 1.14 1.02 0.79 ng or mask	0.94 0.98 0.97 1.02 0.67	1.33 1.40 1.33 1.02 0.92	1.08 1.21 1.12 1.02 0.70	0.86 0.96 0.88 1.02 0.55	1.37 1.53 1.41 1.02 0.88	. Download 1.15 ded from 1.19 htt 1.02	0.91 0.86 0.94 1.02 0.93	1.4 1.3 1.5 1.0 1.0
0.94 0.98 0.97 1.02 0.95 t wearing f	1.33 1.40 1.33 1.02 0.99 face coverin	1.12 1.17 1.14 1.02 0.79 ng or mask	0.94 0.98 0.97 1.02 0.67	1.33 1.40 1.33 1.02 0.92	1.08 1.21 1.12 1.02 0.70	0.86 0.96 0.88 1.02 0.55	1.37 1.53 1.41 1.02 0.88	1.08 1.19	0.91 0.86 0.94 1.02 0.93	1.4 1.3 1.5 1.0 1.0
0.98 0.97 1.02 0.95 t wearing fa 0.72	1.40 1.33 1.02 0.99 face coverin	1.17 1.14 1.02 0.79 ng or mask	0.98 0.97 1.02 0.67	1.40 1.33 1.02 0.92	1.21 1.12 1.02 0.70	0.96 0.88 1.02 0.55	1.53 1.41 1.02 0.88	1.08 1.19	0.86 0.94 1.02 0.93	1.3 1.5 1.0 1.0
0.97 1.02 0.95 t wearing fa 0.72	1.33 1.02 0.99 face coverin	1.14 1.02 0.79 ng or mask	0.97 1.02 0.67	1.33 1.02 0.92	1.12 1.02 0.70	0.88 1.02 0.55	1.41 1.02 0.88	1.08 1.19	0.94 1.02 0.93	1.5 1.0 1.0
1.02 0.95 t wearing f 0.72	1.02 0.99 face coverin	1.02 0.79 ng or mask	1.02 0.67	1.02 0.92	1.02 0.70	1.02 0.55	1.02 0.88	9 1.19 ■ 1.02	1.02 0.93	1.0 1.0
0.95 t wearing fa 0.72	0.99 face coverii	0.79 ng or mask	0.67	0.92	0.70	0.55	0.88	http://bmjopen.br	0.93	1.0
t wearing f	face coverii	ng or mask)					0.97 bmjopen.br 1.02		
0.72		C	, 	0.82	0.23	0.09	0.64	njopen.br	0.64	1 4
0.53	1.02 0.92	0.36 0.29	0.18 0.15	0.71 0.56	0.21 0.18	0.09	0.49	₽ 1.71	0.56 0.48	1.0 1.2 1.0
(Ref = No)	o face cove	ring/mask)						3, 20		
-	-)24 by guest. F		-
-	-					1.11		^o rotected b		-
p	- - eople (Re	eople (Ref = no con	1.22	1.22 1.04 1.25 1.07	1.22 1.04 1.43 1.25 1.07 1.46	1.22 1.04 1.43 1.40 1.25 1.07 1.46 1.43	1.22 1.04 1.43 1.40 1.11 1.25 1.07 1.46 1.43 1.13	1.22 1.04 1.43 1.40 1.11 1.78 1.25 1.07 1.46 1.43 1.13 1.81	1.28 1.08 1.53 1.48 1.14 1.91 Vy st. Poeter of the second sec	1.22 1.04 1.43 1.40 1.11 1.78 Protecting 1.25 1.07 1.46 1.43 1.13 1.81 by -

-

Page	24 of	39
------	-------	----

					В	MJ Open				bmjopen-2021-054200 o		
										021-054		
0-14 days	13.74	12.45	15.15	13.74	12.45	15.15	15.03	13.10	17.24	8017.64	15.38	
15-28 days	4.53	3.95	5.19	4.53	3.95	5.19	4.76	3.99	5.68	₹ 5.58	4.59	
29-60 days	1.62	1.38	1.89	1.62	1.38	1.89	1.63	1.32	2.03	25 2.05	1.62	
61-90 days	0.89	0.69	1.14	0.89	0.69	1.14	1.09	0.78	1.53	0.84 0.84 9 1.14	0.56	
91+ days	1.00	0.76	1.32	1.00	0.76	1.32	0.98	0.66	1.45	፝ ፝ ዩ 1.14	0.77	
Household size	1.02	0.98	1.06	1.02	0.98	1.06	1.04	1.02	1.06	8 1.01	0.95	
Smoke	0.90	0.82	1.00	0.90	0.82	1.00	0.93	0.83	1.05	. <u>,</u> 0.84	0.74	
Region (Ref = Northea	ast)									0.01 000 000 0.01		
Northwest	1.32	1.07	1.64	1.32	1.07	1.64	1.22	0.93	1.61	a 1.36	1.02	
Yorks Humber	0.95	0.75	1.20	0.95	0.75	1.20	0.95	0.71	1.28	<u>e</u> 0.91	0.67	
East midlands	0.80	0.63	1.02	0.79	0.63	1.01	0.70	0.51	0.96	fon 0.91	0.65	
West midlands	0.77	0.61	0.98	0.77	0.61	0.98	0.79	0.59	1.07	a 0.71	0.51	
East	0.54	0.43	0.68	0.54	0.43	0.68	0.53	0.39	0.71	0.52	0.38	
London	0.95	0.77	1.18	0.94	0.76	1.17	0.89	0.67	1.17	<mark>피</mark> . 양 1.01	0.75	
South East	0.69	0.56	0.86	0.69	0.56	0.86	0.68	0.51	0.92	0.69	0.50	
South West	0.41	0.32	0.53	0.41	0.32	0.52	0.41	0.29	0.57	0.4 1	0.28	
Occupation (Ref = Heat	alth profession	onals)								mj. 0.41		
Corporate managers	1 70	1 41	2.26	1 77	1 40	2.24	1.96	1 22	2.50	S S	1 45	
and directors Other managers and	1.79	1.41	2.26	1.77	1.40	2.24	1.86	1.33	2.59	April 2.18	1.45	
proprietors	2.46	1.87	3.24	2.41	1.83	3.17	2.05	1.36	3.10	₩ <u>3.00</u>	1.91	
Science research										202		
engineering and technology										2024 by gu 2.01		
professionals	1.51	1.15	1.98	1.49	1.13	1.96	1.11	0.68	1.80	<u>م</u> 2.01	1.31	
Teaching and										est.		
educational professionals	1.60	1.32	1.95	1.58	1.30	1.93	1.43	1.13	1.81	P 0,212	1.40	
Business media and	1.00	1.52	1.75	1.20	1.50	1.75	1.15		1.01	. Protected	1.10	
public service	1 - 4	1 10	1.00	1 5 1	1 1 7	1.0.4	1.50	1.00	0.10		1.1.7	
professionals	1.54	1.19	1.98	1.51	1.17	1.94	1.52	1.09	2.12	by copyright	1.15	
										pyr		

Page 25 of 39						BI	NJ Open				bmjopen-		
1 2 3 4 5	Science engineering and technology associate										bmjopen-2021-054200 on		
6 7 8	professionals Health and social care associated	1.51	1.02	2.23	1.49	1.01	2.21	1.38	0.74	2.58	2.01 October 2.16	1.14	3.56
9 10	professionals	1.48	1.04	2.10	1.46	1.03	2.08	1.30	0.86	1.96	^{er} 2.16	1.15	4.04
11 12	Protective service occupations Culture media and	1.82	1.33	2.49	1.80	1.32	2.47	2.59	1.62	4.14	2021. 1. 1.86	1.16	2.98
13 14 15	sports occupations Business and public	1.46	1.05	2.04	1.43	1.03	2.00	1.62	1.05	2.49	Downloaded	0.84	2.53
16 17	service associated professionals Administrative	1.73	1.37	2.19	1.72	1.36	2.17	1.62	1.18	2.21	from 2.18	1.45	3.29
18 19	occupations Secretarial and	1.97	1.59	2.45	1.95	1.58	2.42	1.90	1.47	2.45	2.41	1.57	3.71
20 21	related occupations Skilled agricultural	2.41	1.80	3.23	2.39	1.78	3.20	2.34	1.71	3.20	http://bmjop	0.33	4.54
22 23	and related trades Skilled metal	0.89	0.46	1.73	0.87	0.45	1.69	1.15	0.33	3.95	en. 1.11 .com/ 2.80	0.49	2.52
24 25 26	electrical and electronic trades Skilled construction	2.25	1.68	3.02	2.20	1.64	2.96	2.92	0.78	10.84	2.80	1.86	4.23
27 28	and building trades Textiles printing and	2.41	1.76	3.30	2.36	1.73	3.23	0.48	0.05	5.06	₽ ₽ 1.32	2.16	5.11
29 30	other skilled trades	1.42	0.87	2.32	1.39	0.85	2.27	1.77	0.89	3.51	²³ , 1.62	0.80	3.27
31 32 33	Caring personal service occupations Leisure travel and	2.03	1.64	2.52	2.01	1.62	2.50	1.93	1.53	2.45	2024 2.75 gr	1.68	4.48
34	related personal service occupations	1.84	1.17	2.89	1.82	1.16	2.86	1.43	0.80	2.58	guest: 4.31	2.00	9.25
35 36 37	Sales occupation Customer service	1.95	1.51	2.52	1.92	1.48	2.47	1.72	1.25	2.35	Pot 3.06	1.88	5.00
37 38 39	occupations Process plant and	1.73	1.17	2.57	1.72	1.16	2.54	1.49	0.93	2.39	ected 2.77	1.42	5.40
40 41 42	machine operatives	2.10	1.44	3.04	2.05	1.42	2.98	2.94	1.24	6.98	by copyright.	1.54	4.10
43											.+		

BMJ	Open

Page 26 of 39

					В	MJ Open				5.19 pmjopen-2021-054200 on		
										2021-05		
Transport and mobile machine driver and										4200 c		
operatives Elementary trades and related	2.36	1.76	3.17	2.32	1.73	3.11	1.62	0.64	4.06	S 3.19	2.07	4.9
occupations Elementary	2.75	1.53	4.94	2.69	1.49	4.85	2.92	0.54	15.73	October 3.53	1.78	7.0
administration and service occupations	2.16	1.71	2.73	2.14	1.69	2.71	1.90	1.39	2.60	2021. 1. 3.03	1.97	4.6
Variance (Household) Residual intraclass	3.34	3.05	3.63	3.34	3.05	3.63	2.38	1.64	3.12	Downloaded	0.94	3.0
correlation (Household) Variance	0.44	0.41	0.47	0.44	0.41	0.47	0.32	0.23	0.42	from 0.27	0.15	0.4
(Individuals) Residual intraclass correlation	1.02	0.78	1.26	1.02	0.78	1.26	1.88	1.14	2.62	2.11 0.56	1.03	3.1
(Individuals)	0.57	0.55	0.59	0.57	0.55	0.59	0.56	0.54	0.59	0.56	0.53	0.5
N	409,009			409,009			217,920			191,089		
No. of household	72,866			72,866			50,405			,∎. 44,822		
No. of participant	100,138			100,138			53,015			4 7,123		
										pn April 23, 2024 by guest. Protected by copyright.		


Page 2	27 of	39
--------	-------	----


BMJ Open

Table S4. Multilevel logistic r Outcome:		dels of Covid) - 04 Nov 202			eriod, ONS () - 19 Dec 2020) - 02 Feb 2020)
Test positive	10 Way 2020			03 1107 2020			20 Dec 2020		
	Odds Ratio	Lower 95% CI	Upper 95% CI	Odds Ratio	Lower 95% CI	Upper 95% CI	O Offelds Ratio	Lower 95% CI	Upp CI
Female	0.83	0.69	0.99	0.92	0.80	1.06	er 0.77	0.66	0.90
BAME	1.27	0.89	1.81	1.36	1.04	1.79	²⁰² 0.97	0.72	
Age group (Ref = $60-64$)							•		
18-29	1.80	1.22	2.67	1.26	0.92	1.72	Download 1.68 1.14 1.36 1.22	1.18	
30-39	0.99	0.68	1.44	1.03	0.77	1.38	0a 1.14	0.82	
40-49	0.85	0.59	1.24	1.07	0.80	1.44	<u>a</u> 1.36	1.00	
50-59	1.20	0.84	1.70	0.99	0.74	1.33	G 1.22	0.89	
Visit date	1.04	1.04	1.04	1.00	1.00	1.00	a 1.01	1.01	
Autonomy	0.58	0.36	0.92	0.98	0.94	1.02	0.96	0.92	
Face covering or masks (Ref = no	ot wearing face	covering or m	ask)				njop		
Yes my face is already covered Yes at work/school/other	0.27	0.04	1.90	0.59	0.34	1.03	en. 1.38	0.59	
situations only Yes usually both	0.30	0.05	1.71	0.50	0.31	0.82	http://bmjopen.bmj.com/ 0.58	0.33	
work/school/other	0.20	0.04	1.13	0.44	0.27	0.73	S 0.58 ≥	0.31	
Autonomy x Face covering/mask Autonomy x Yes my face is	s (Ref = No fac	e covering/ma	sk)				April 23,		
Autonomy x Yes at Autonomy x Yes at work/school/other situations	1.73	1.04	2.89	-	-	J	- 23, 2024	-	
only Autonomy x Yes usually both	1.63	1.02	2.61	-	-	-	 2024 by gue	-	
work/school/other	1.75	1.09	2.80	-	-	-	Protected 27.66	-	
Contact with COIVD-19 positive	people (Ref =	no contact)					rote		
0-14 days	14.01	11.30	17.38	15.03	12.35	18.28	če 27.66	21.02	
15-28 days	3.56	2.50	5.07	5.16	4.00	6.65	षु 7.10	5.40	

			BMJ	Open			bmjopen-2021-054200			
							n-202			
							21-05-			
29-60 days	1.79	1.01	3.15	2.32	1.76	3.05	1200	1.93	1.41	2.6
61-90 days	1.73	0.44	6.83	1.15	0.65	2.03	on	1.20	0.81	1.7
91+ days	0.90	0.38	2.14	1.23	0.69	2.22	25 (1.15	0.75	1.7
Household size	1.04	0.96	1.13	1.05	0.99	1.11	October	1.01	0.93	1.0
Smoke	0.82	0.66	1.02	0.95	0.81	1.11	ber	0.93	0.78	1.1
Region (Ref = Northeast)							2021.			
Northwest	1.79	1.18	2.70	1.46	0.99	2.16	1. D	0.97	0.64	1.4
Yorks Humber	1.25	0.81	1.92	1.32	0.89	1.96	Downloaded from	0.36	0.22	0.5
East midlands	0.73	0.45	1.20	1.15	0.75	1.77	load	0.52	0.32	0.8
West midlands	0.55	0.34	0.90	0.91	0.61	1.38	ed f	0.76	0.49	1.2
East	0.25	0.15	0.42	0.53	0.35	0.80	rom	0.66	0.43	1.02
London	0.55	0.35	0.87	0.85	0.58	1.26	http	1.36	0.92	2.0
South East	0.35	0.22	0.56	0.70	0.47	1.06	http://bmjop	0.89	0.59	1.34
South West	0.29	0.16	0.51	0.45	0.28	0.72		0.34	0.21	0.5
Variance (Household) Residual intraclass correlation	6.01	4.99	7.03	5.21	4.43	5.99	en.bmj.com/ on	7.21	5.98	8.44
(Household)	0.49	0.43	0.54	0.50	0.45	0.54	.co	0.58	0.54	0.6
Variance (Individuals) Residual intraclass correlation	3.04	2.16	3.92	2.03	1.34	2.72		1.94	1.16	2.7
(Individuals)	0.73	0.70	0.76	0.69	0.65	0.72	April	0.74	0.70	0.7
Ν	187453			142056			23,	79500		
No. of household	54383			57203			2024	47594		
No. of participant	73262			75682			.4 Ф	60252		

 v guest. Protected by copyright.





Page 31 o	of 39
-----------	-------

max

1

1

1

64

1

1

1

1

7

1

1

1

10 +

10 +

7

1

1

1

1

1

1

min

0

0

0

20

0

0

0

0

0

0

0

0

0

0

1

1

0

0

0

0

0

0

0

Male

mean

0.0120

0.0000

0.0763

44.5303

0.1266

0.2212

0.2639

0.2859

0.1024

4.5345

0.0163

0.0281

0.5054

0.4502

6.9541

2.7384

3.1415

0.8102

0.0730

0.0350

0.0402

0.0179

0.0238

sd

(11.5765)

(1.6413)

(1.9721)

(1.2039)

(2.1295)

bmjopen-2021-05420¢

Fengale

sd

(11.4819)

(1.9129)

(1.9794)

(1.1836)

(1.9749)

mean

0.0917 1.0900

0.0870 44.7364 0.1271 0.2988 0.2659

0.3**0**29

0.0953

3.9381

0.0297

8

0.4880 0.4886 6.9946 2.5819 2.9836

0.7243 0.0925

0.0713

0.0475 0.0498 0.0246 0.0246

1			
2 3			
3 4	Table S5. Descriptive statistics N		
5		All	
6		mean	sd
7 8	COVID-19 positive	0.0118	
9	Female	0.5328	
10	BAME	0.0766	
11	Age at visit	44.6401	(11.5266)
12	Age group		
13 14	18-29	0.1269	
15	30-39	0.2146	
16	40-49	0.2650	
17	50-59	0.2949	
18 19	60+	0.0986	
20	Autonomy	4.2061	(1.8174)
21	Face mask		
22	No face mask	0.0149	
23	Yes my face is already covered	0.0290	
24 25	Yes at work/school/other situations		
26	only	0.4855	
27	Yes usually both work/school/other	0.4707	
28	Number of test	6.9757	(1.9761)
29	Household size	2.6550	(1.1957)
30 31	Work outside home days	3.0201	(2.0517)
32	Contact with COVID-19 positive		
33	No contact	0.7911	
34	0-14 days	0.0834	
35	15-28 days	0.0384	
36 37	29-60 days	0.0441	
38	61-90 days	0.0189	
39	91+ days	0.0242	
40	JI duys	0.0212	
41 42			
42 43		-	
44		For peer	review only - h
45			
46			

only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

			BMJ Open		mjopen-2021-054200 0.490 0.490
Work social distancing					1200
Easy to maintain 2m	0.4914	0	1	0.5602	0.4912
Relatively easy to maintain 2m Difficult to maintain 2m but can be	0.1621	0	1	0.1818	0.1848 O 0.1940
lm	0.1362	0	1	0.1272	0.1 § 40
Very difficult to be more than 1m	0.2103	0	1	0.1309	0.2 <mark>9</mark> 99
Work location					021
Working from home Working somewhere else(not your	0.2417	0	1	0.2561	0.2 0 91
home) Both(from home and somewhere	0.6186	0	1	0.5985	0.6362 0.13748 0.13748
else)	0.1397	0	1	0.1454	0.1 48
Work travel method					mo.
Underground/metro/light rail/tram	0.0252	0	1	0.0259	0.0246
Train	0.0383	0	1	0.0443	0.0331
Bus/minibus/coach	0.0266	0		0.0206	0.0218
Motorbike/scooter or moped	0.0040	0	1	0.0071	0.0014
Car or van	0.6985	0	1	0.6995	0.69.77
Taxi/minicab	0.0038	0	1	0.0037	0.0040
Bicycle	0.0358	0	1	0.0470	0.0260
On foot	0.1355	0	1	0.1181	0.1508
Other method	0.0323	0	1	0.0339	0.0508
Smoking	0.3007	0	1	0.3257	0.2788
Work direct with patients	0.2184	0	1	0.1501	0.2 283
Occupation					by
Corporate managers and directors	0.0787	0	1	0.1101	0.0ි 12
Other managers and proprietors Science research engineering and	0.0371	0	1	0.0495	0.0 ² 63 망
technology professionals	0.0516	0	1	0.0842	0.0231
Health professionals Teaching and educational	0.0640	0	1	0.0275	0.0 <mark>ම්</mark> 60 ද
professionals	0.1065	0	1	0.0665	0.1816

Page 32 of 39

0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.1900 0.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page	33	of	39
------	----	----	----

3 4

je 33 of 39			E	3MJ Open		omjoper
						bmjopen-2021-05420 6 0 0.00
	Business media and public service	0.0(70	0	1	0.0707	54200
	professionals Science engineering and technology	0.0678	0	1	0.0796	0.05/6
	associate professionals Health and social care associated	0.0152	0	1	0.0203	0.0906
	professionals	0.0178	0	1	0.0097	$0.0 \frac{2}{5} 50$
	Protective service occupations	0.0210	0	1	0.0312	$0.0\frac{\Phi}{10}21$
	Culture media and sports occupations Business and public service	0.0252	0	1	0.0266	0.0,239
	associated professionals	0.0812	0	1	0.0891	0.0 43
	Administrative occupations	0.1023	0	1	0.0603	$0.1\overline{8}91$
	Secretarial and related occupations	0.0257	0	1	0.0031	0.0 455
	Skilled agricultural and related trades Skilled metal electrical and electronic	0.0080	0	1	0.0128	0.00
	trades Skilled construction and building	0.0303	0	1	0.0634	0.0
	trades Textiles printing and other skilled	0.0259	0		0.0537	0.00015
	trades	0.0097	0	1	0.0123	0.0074
	Caring personal service occupations Leisure travel and related personal	0.0722	0	1	0.0188	0.1390
	service occupations	0.0094	0	1	0.0051	0.0432
	Sales occupation	0.0397	0	1	0.0263	0.0≸15
	Customer service occupations	0.0142	0	1	0.0096	0.0783
	Process plant and machine operatives Transport and mobile machine driver	0.0149	0	1	0.0279	0.0036
	and operatives Elementary trades and related	0.0261	0	1	0.0516	0.0 0 38
	occupations Elementary administration and	0.0044	0	1	0.0084	0.0 6 09
	service occupations Region	0.0511	0	1	0.0527	0.0497
	Northeast	0.0503	0	1	0.0483	ອ ດ ທ ຊ າ 1
	Northwest	0.1435	0	1	0.1422	0.0221
	1101111WESt	0.1455	U	I	0.1422	. р97 0.0 2 97 0.050у46 0.10ругідht.

				BMJ Open		bmjop	
						bmjopen-2021-054222 0.1200 0.0275	
						21-0	
	Yorks Humber	0.1021	0	1	0.1019	0 1822	
	East midlands	0.0776	0	1	0.0776	0.0975	
	West midlands	0.0943	0	1	0.0960	0.0829	
	East	0.1241	0	1	0.1262	0.1823	
	London	0.1743	0	1	0.1759	0.1223 0.1230	
`	South East	0.1474	0	1	0.1480		
)	South West			1		0.1869 0.0884	
<u>2</u>	N	0.0863 409,009	Ū.	-	191.089	21 2920	
5		06			,	nlo	
ŀ						bade	
5						ed fr	
,						Ö	
3						http	
))						://br	
,						njop	
2						oen.	
3						bmj.	
+						.c	
5						n / <u>o</u>	
7						∩ Ar	
3						oril 2	
)						ů N	
, 						2024	
2						t by	
3						gue	
+						st. F	
5						Prote	
7						ecte	
3						d by	
,)						cop	
						vnloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.	
2							
5 L		For peer review o	nly - http://bmj	open.bmj.co	m/site/about/guidelin	es.xhtml	
r -							

Page 34 of 39

 BMJ Open 2. Sample of Questionnaire (All study protocol and questionnaires are available online <u>https://www.ndm.ox&c.uk/covid-19/covid-19-infection-survey</u>)

			- C(DMI	PLE	TE /	AT E	AC	H F(DLL	LOW-U	RF5 INDIV P VISIT (I	NO	T A	r ei	NR	DLN	EN	T)			ти		A 1.17	-
Uni	COMPLET que house- d code		FUR		.niL						Parti	cipant of birth	D	D	M	M	M					inc	.112	ANT	
	que parti- Int code			T	Τ	Π	T		Τ	Γ		Date/time of visit	D	D	М	М	м	2 0) 2	2 Y		h	h:	m	m
Sw	ab ⊡Yes en ⊡No	If ye	es: code		T	T			Ť			If yes: shipment	ID								Γ	Ē	Ι	Γ	
	od ⊡Yes en ⊡No	lf ye baro	es: code									If yes: shipment	ID						T			Ī		T	
_	e/time nples taken	D	DM	М	М	Y	Y	Y	h	h	: m n	7							-						٦
						A:	wo	DR	K. S	CI	100	AND N	UR	SE	RY										ī
	 Looking Not in pa Retired (Child un Child un Child un 4-5y and Attendin 	aid w (inclu ider 4 ider 4 d olde g coll	ork ar de do -5y no -5y at er at s lege o	id no ing t ot at tend choo r oth	ot loo volur tend ling i bl/ho her fi	oking ntary ing n nurs me-s urthe	for p work urse ery, p schoo r edu	oaid (he ry, r ore-s ol (in ucat	re) ore-s schoo iclud ion p	cho ol, c ing rovi	ol, child hildmin if tempo ider (inc	minder der prarily abse	ent)		(<u>go</u>	to A	2 if			(g (g (g	o to o to otr	(g Se (g nerv ly a (g	o to o to o to o to vise o to		
	Do you ha			lem	ploy	men	t in a					part of an 6y and old						o S	ecti	on B	if R	Retir	red)		1
2.				all:	Has	you	r mai									ke t							[)	
	If currently Yes		nthy we	nkin																					
3.	Yes o, and not o					; III y	ouri																		-
3.	Yes <u>o, and not c</u> <u>If yes</u> : (a) V (b) /	What And ir	is you 1 this j	r jol ob/t	ousin																				
3.	Yes o, <u>and not c</u> <u>If yes</u> : (a) V (b) / (c) V	What And ir Which	is you 1 this j 1 of th	r jol ob/t ese	ousin emp	loym	ent s		ors d	o yo		in now? (s													-
3.	Yes <u>o, and not c</u> <u>If yes</u> : (a) V (b) / (c) V	What And ir Which) Tea	is you n this j n of th aching	r jol ob/t ese and	ousin emp I edu	loym Icatio	ent s		ors d	o yo		in now? (s	n ca	re <u>(c</u>	o to			riet	ic)						-
3.	Yes <u>o, and not o</u> <u>If yes</u> : (a) V (b) / (c) V	What And ir Which Tea Soc	is you n this j n of th nching cial ca	r joł ob/t ese and re <u>(c</u>	ousin emp I edu <u>to to</u>	loym Icatio <u>A5)</u>	ent s n	ecto	ors d	o yo		in now? (s Health Trans	n ca port	re <u>(c</u> (inc	<u>io to</u> I. st	oraș	je, k			cafe	3)				-
3.	Yes <u>o, and not c</u> <u>If yes</u> : (a) V (b) / (c) V	What And ir Which Tea Soc Ret	is you n this j n of th iching tial ca ail seo	r jol ob/t ese and re <u>(c</u> ctor	ousin emp l edu <u>ro to</u> (incl.	loym Icatio <u>A5)</u> who	ent s on olesa	ecto				in now? (<u>s</u> Health Trans Hospi	n ca port tality	re <u>(c</u> (inc / (e.	<u>roto</u> I. st g. h	orag otel	je, k , res	aun	ant,			ois	ts)		-
3.	Yes o <u>, and not c</u> <u>If yes</u> : (a) V (b) A (c) V	What And ir Which Tea Soc Ret Foo Info	is you n this j n of the iching ical ca ail see ad proo	r jol ob/t ese and re <u>(c</u> tor duct	ousin emp l edu <u>to to</u> (incl. ion a echno	loym icatio <u>A5)</u> who and a ology	ents on Jesa gricu / and	iecto le) lituri cor	e (in	cl. fa	ou work arming)	in now? (<u>s</u> Health Trans Hospi Perso	n ca port tality nal cial	re <u>(g</u> (inc (e.) serv serv	<u>io to</u> I. st g. h ices ices	orag otel s (e. s (in	ge, k , res g. ha cl. in	irdn sura	ant, ess ance	ers, e)		xois	ts)		
3.	Yes o <u>, and not c</u> <u>If yes</u> : (a) V (b) A (c) V	What And ir Which Tea Soc Ret Foo Info Mar	is you n this j n of the iching ial ca ail see ad pro- matic nufact	r jol ob/t ese and re <u>(c</u> tor duct on te uring	ousin emp l edu <u>to to</u> (incl. ion a echno g or (loym icatio <u>A5)</u> who and a ology	ents on Jesa gricu / and	iecto le) lituri cor	e (in	cl. fa	ou work arming)	in now? (<u>s</u> Health Trans Hospi Perso Finan Civil s	n ca port tality nal cial ervi	re <u>(c</u> (inc / (e. serv serv serv ce o	<u>io to</u> I. st g. h ices ices r Lo	orag otel s (e. s (in s cal	ge, k , res g. ha cl. in Gov	irdn sura ernn	ant, ess ance nen	ers, e)		xois	ts)		
3.	Yes <u>o, and not c</u> <u>If yes</u> : (a) V (b) A (c) V C C C C C C C C C C C C C	What And ir Which Tea Soc Ret Foo Foo Info Mar Arm	is you in this j in of the iching ical ca ail see ail see of pro- imation nufact ned fo	r jol ob/t ese and re <u>(c</u> tor (duct on te urin) rces	emp emp l edu <u>to to</u> (incl. ion a echno g or	loym (cation (A5) (who and a ology cons	ent s n lesa gricu / and truct	iecto le) lituri cor	e (in mmu	cl. fa nica	ou work arming)	in now? (<u>s</u> Health Trans Hospi Perso Finan Civil s Arts, e	n ca port tality nal cial ervi ente	re <u>(g</u> (inc / (e.) serv serv ce o rtain	<u>io to</u> I. st g. h ices ices r Lo me	orag otel s (e. s (in ocal nt o	ge, k , res g. ha cl. in Gov r rec	irdn sura ernn reati	ant, ess ance nen ion	ers, e) it	tatto		ĺ		
3. <i>If n</i>	Yes o <u>, and not c</u> <u>If ves</u> : (a) V (b) V (c) V	What And ir Which Tea Soc Ret Foo Info Mar Arm Oth	is you in this j in of the iching cial ca ail sec ad pro- imation nufact ned fo er em	r jol ob/t ese and re <u>(c</u> tor duct duct on te urine rces ploy	emp l edu <u>to to</u> (incl. ion a echno g or men	loym (catio <u>A5)</u> who and a ology cons	ent s on lesa gricu gricu and tructi	iecto ilturi cor ion	e (ind mmu :ify _	cl. fa nica	ou work arming)	in now? (<u>s</u> Healtt Trans Hospi Perso Finan Civil s Arts, e (go to	n ca port tality nal cial ervi ente <u>A6</u>	re <u>(g</u> (inc / (e serv serv ce o rtain <i>if n</i> c	<u>io to</u> I. st g. h ices ices r Lo me <u>ot n</u>	orag otel s (e. s (in s cal nt o ow i	ge, ko , res g. ha cl. in Gov r rec <u>vork</u>	irdn sura ernn reati ng i	ant, ess ance nen ion <u>n H</u>	ers, e) it	tatto		ĺ	care	2
3. <i>If n</i>	Yes <u>o, and not c</u> <u>If yes</u> : (a) V (b) A (c) V C C C C C C C C C C C C C	What And ir Which Tea Soc Ret Foo Info Mar Arm Oth	is you in this j in of the iching cial ca ail sec ad pro- imation nufact ned fo er em	r jol ob/t ese and re <u>(c</u> tor duct duct on te urine rces ploy	emp l edu <u>to to</u> (incl. ion a echno g or men	loym icatio <u>A5)</u> who and a ology cons t sec Is th	ent s on Iesa Igricu / and tructi tructi	iecto iltun cor ion spec	e (ind mmu cify _ ntly	cl. fa nica	ou work arming)	in now? (<u>s</u> Healtt Trans Hospi Perso Finan Civil s Arts, e (go to	n cai port tality nal cial cial ervi ente <u>A6</u> ry c	re <u>(g</u> (inc / (e. serv serv ce o rtain <u>if no</u> are (ices ices r Lo me o <u>t n</u>	orag otel s (e. s (in ocal nt o <u>ow i</u> . GF	ge, ko , res g. ha cl. in Gov r rec <u>vork</u> P, de	irdn sura ernn reati <u>ng i</u>	ant, ess ance nen ion <u>n H</u>	ers, e) it	tatto		ĺ	<u>care</u>	2
3. <i>If n</i>	Yes o <u>, and not c</u> <u>If ves</u> : (a) V (b) V (c) V	What And ir Which Tea Soc Ret Foo Info Mar Arm Oth	is you in this j in of the iching cial ca ail sec ad pro- imation nufact ned fo er em	r jol ob/t ese and re <u>(c</u> tor duct duct on te urine rces ploy	ousin emp l edu <u>to to</u> (incl. ion a echno g or men	loym icatio <u>A5)</u> who and a ology cons t sec Is th	ent s on lesa gricu gricu and tructi	iecto iltun cor ion spec	e (ind mmu cify _ ntly	cl. fa nica	ou work arming)	in now? (<u>s</u> Healtt Trans Hospi Perso Finan Civil s Arts, e (go to	n ca port tality nal cial ervi ervi ente <u>A6</u> ry c ndar	re <u>(g</u> (inc / (e.) serv serv ce o rtain <u>if no</u> are (y ca	ices ices r Lo me <u>ot no</u> (e.g re (orag otel s (e. s (in ocal nt o <u>ow i</u> . GF e.g.	ge, ko , res g. ha cl. in Gov r rec <u>vorki</u> P, de hos	irdn sura ernn reati <u>ing i</u> ntist	ant, ess ance nen ion <u>n H</u> :)	ers, 1 e) It I <u>ealtř</u>	tatto		ĺ	<u>care</u>	2
3. <i>lf n</i> 4.	Yes o <u>, and not c</u> <u>If ves</u> : (a) V (b) V (c) V	What And ir Which Tea Soc Ret Foo Info Mar Arm Oth king i	is you n this j n of the iching cial ca ail see od proo matic nufact ned fo er em <u>n hea</u>	r jok ob/t ese and re <u>(c</u> tor (duct duct duct on te uring rces ploy th c	ousin emp l edu <u>to to</u> (incl. ion a echno g or men <u>are</u> :	loym (catio (<u>A5)</u> (who and a olog) cons (t sec Is th ((rsing	ent son olesa igricu / and tructi :tor, : iat cu <u>/se/en</u> care	ecto le) liture con spec rrer <u>ct or</u>	e (ind mmu tify ntly <u>ne</u>) me o	cl. fa nica	arming) tion	in now? (s Health Trans Hospi Perso Finan Civil s Arts, e (<i>ao to</i> Prima Secor Other ial care ho	n ca port tality nal cial ervi ervi ervi ervi ervi o <u>A6</u> ndar hea me?	re <u>(c</u> (inc y (e. serv serv ce o rtain <u>if nc</u> y ca lthc	io to I. st g. h ices ices r Lo me o <u>t no</u> (e.g re (are	orag otel s (e. s (in ocal nt o <u>ow i</u> . GF e.g. (e.g	ge, k , res g. ha cl. in Gov r rec <u>vork</u> P, de hos . me	irdn sura ernn reati ng i ntist pital ntal	ant, ess ance nen ion <u>n H</u> i)) hea	ers, i e) it <u>lealth</u> alth)	o or	<u>Soc</u> Yes	cial	<u>care</u>	2

								N N		
7.	If currently working now (see	e A1, A2): Ci	urrently, do you wo	ork? (<u>se</u> le	ct one)			С С		
	From home (in the same g	grounds or bu	uilding as your hom	ie)				$\hat{\mathbf{O}}$	go to Sec	tion B)
	Somewhere else (not at y	our home)						8	(go	to A8)
	Both (work from home and	d work some	where else)					ð	(go	to A8)
8.	If currently working not at yo	our home, or	in education or atte	ending sc	hool or i	nursery,	<u>etc</u> : On a	verage	, on how r	many
	days of the week are you cu	urrently worki	ing somewhere els	e (not at	your ho	me, defi	ned as th	e <u>®</u> ame	grounds	or
	building as your home), or c	currently atter	nding, in person, y	our place	of educ	ation, so	hool, nur	sery, pr	e-school o	r
	childminder? (select one)		0 1	2	03			50	6	07
9.	If currently working not at you	ur home, or i	n education or atte	nding sch	nool or n	ursery, e	etc: How	d o y ou r	mainly get	to and
	from work/nursery/education	1 provider? (s	elect one only: if us	se multipl	e modes	s, choose	e the long	jest par	t of your jo	oumey
	in time)									
	Underground, metro, light			🗆 Bus, m					ooter or m	
	Car or van			Bicycle			On for		Other n	
10.	If currently working or in edu									1-2m
	between yourself and other						etc? (sel	egone)	
	Easy to maintain 2m, it is in the second			-				ã		
	Relatively easy to maintain						people	e		
	Difficult to maintain 2m, bu									
_	Very difficult to be more the						act with o		n a regula	ar basis
			UR HEALTH	STATU	S TO	DAY		_		
1.1	lave you had any of these sy		the last 7 days?					2		
ev	er 🗆 Yes 🗆] No	Headache	Yes	□ No		Muscle a	actie	Yes	□ No
Ne	akness/tiredness 🗆 Yes 🛛] No	Nausea/vomiting	Yes	□ No		Abdomi	nalpain	Yes	No
Dia	rhoea 🛛 Yes 🗆] No	Sore throat	Yes	□ No		Cough	6	Yes	□ No
Sho] No	Loss of taste	Yes	□ No		Loss of	smell	Yes	□ No
	(a) Please confirm: have you	Lhad any of t		the last	7 days			ö		
			ancoc oymptomo n	i uic iusi	i uuyo	: 0 103		Ō.		
	(b) If yes: date first symptom							0	/ M 2 0	0 2 Y
2.	Are you currently self-isolatin No Yes because you have/ha Yes because you live with	ing due to CC ave had symp	ptoms of COVID-1	9 or a po	sitive te	st			one)	oms
2.	Are you currently self-isolatin No Yes because you have/ha	ing due to CC ave had symp i someone wh ated to you ha	ptoms of COVID-1 no has/has had syn aving had an increa	9 or a po nptoms o	sitive te: r a posit	st ive test,	but you h	(<u>select</u> OM aven't h	<u>one</u>) ad sympto	
2.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela	ing due to CC ave had symp a someone wh ated to you ha ning after trav	ptoms of COVID-1 no has/has had syn aving had an increa vel abroad)	9 or a po nptoms o ased risk	sitive te: r a posit of gettin	st ive test, g COVIE	but you h)-19 (e.g.	(select b) aven't h aven't h	<u>one</u>) had sympto been in c	
3.	Are you currently self-isolatii Ves because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Yes, for other reasons rela Do you currently think you h	ing due to CC ave had symp a someone wh ated to you ha ning after trav ated to reduci nave symptor	ptoms of COVID-1 no has/has had sym aving had an increa vel abroad) ing your risk of gett ns consistent with	9 or a po nptoms o ased risk ting COVI COVID-1	sitive tea r a posit of gettin D-19 (e. 9 infect	st ive test, g COVIE g. going ion?	but you h)-19 (e.g. into hosj	(<u>select</u>) bmj aven't h faving	one) had sympto been in c ielding) Yes	ontact
3.	Are you currently self-isolatii Ves because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Yes, for other reasons rela Do you currently think you h	ing due to CC ave had symp a someone wh ated to you ha ning after trav ated to reduci nave symptor	ptoms of COVID-1 no has/has had sym aving had an increa vel abroad) ing your risk of gett ns consistent with	9 or a po nptoms o ased risk ting COVI COVID-1	sitive tea r a posit of gettin D-19 (e. 9 infect	st ive test, g COVIE g. going ion?	but you h)-19 (e.g. into hosj	(<u>select</u>) bmj aven't h faving	one) had sympto been in c ielding) Yes	ontact
3.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela Ves, for other reasons rela Do you currently think you h Do you have any physical o (excluding any long-lasting (ing due to CC ave had symp a someone wh ated to you ha ning after trav ated to reduci ave symptor or mental hea COVID-19 sj	ptoms of COVID-1 no has/has had sym aving had an increa vel abroad) ing your risk of gett ms consistent with ith conditions or ill ymptoms)?	9 or a pos nptoms o ased risk ting COVI COVID-1 nesses la	sitive ter r a posit of gettin D-19 (e. 9 infect asting or	st ive test, g COVIE g. going ion? expecte	but you h)-19 (e.g. into hos ed to last	(<u>select</u> bmjænth Beving Beving Apri	one) had sympto been in c ielding) Yes hths or mo	ontact No ore No
3.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Do you currently think you h Do you currently think you h Do you currently think you h (excluding any long-lasting (<u>fyes:</u> (a) Do any of your co	ing due to CC ave had symp a someone wh ated to you ha ning after trav ated to reduci ave symptor or mental hea COVID-19 sy onditions or ill	ptoms of COVID-1 no has/has had sym aving had an increa vel abroad) ing your risk of gett ns consistent with lth conditions or or ill ymptoms)? Inesses reduce you	9 or a po nptoms o ased risk ting COVI COVID-1 nesses la ur ability	sitive te r a posit of gettin D-19 (e 9 infect asting or to carry-	st ive test, g COVIE g. going ion? expecte out day-	but you h)-19 (e.g. into hos ed to last	(<u>select</u> bmjænth Beving Beving Apri	one) had sympto been in c ielding) Yes hths or mo	ontact No ore No
3. 4.	Are you currently self-isolatii Ves because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela Do you currently think you h Do you urrently think you h Do you have any physical or (excluding any long-lasting ' <u>f' yes</u> : (a) Do any of your co Yes, a	ing due to CC ave had symp someone wh ated to you ha ning after trav ated to reduci nave symptor or mental hea COVID-19 sy onditions or ill a lot	ptoms of COVID- no has/has had sym aving had an increa vel abroad) ing your risk of gett ms consistent with lth conditions or ill ymptoms)? Inesses reduce yoo _Yes, a little	9 or a po nptoms o ased risk ting COVI COVID-1 nesses la ur ability	sitive ter r a posit of gettin D-19 (e. 9 infect asting or	st ive test, g COVIE g. going ion? expecte out day-	but you h)-19 (e.g. into hos ed to last	(<u>select</u> bmjænth Beving Beving Apri	one) had sympto been in c ielding) Yes hths or mo	ontact No ore No
3. 4.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela Do you currently think you h Do you have any physical or (excluding any long-lasting (<u>If yes</u> : (a) Do any of your co Pes, a Have you ever smoked ciga	ing due to CC ave had symp someone wh ated to you ha ning after trav ated to reduci ave symptor or mental hea COVID-19 sy onditions or ill a lot	ptoms of COVID- no has/has had sym aving had an increa vel abroad) ing your risk of gett ms consistent with lth conditions or ill ymptoms)? Inesses reduce yoo _Yes, a little	9 or a po nptoms o ased risk ting COVI COVID-1 nesses la ur ability	sitive te r a posit of gettin D-19 (e 9 infect asting or to carry-	st ive test, g COVIE g. going ion? expecte out day-	but you h)-19 (e.g. into hos ed to last	(<u>select</u> bmjænth Beving Beving Apri	ad sympto been in c ielding) Yes ths or mo Yes ? (<u>select o</u>	ontact No ore No one)
3. 4. 5.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Do you currently think you h Do you currently think you h Have you ever smoked ciga Do you currently smoke or v	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci nave symptor or mental hea COVID-19 sy onditions or ill a lot arettes regula vape at all?	ploms of COVID-1 no has/has had syn aving had an incree el abroad) ing your risk of gett ms consistent with lth conditions or ill inconsistent with lth conditions or ill imptoms)? Inesses reduce yoo _Yes, a little rfy?	9 or a po nptoms o ased risk ting COVI COVID-1 nesses la ur ability	sitive ter r a posit of gettin D-19 (e. 9 infect asting or to carry- Not at	st ive test, g COVIE g, going ion? expecte out day- all	but you h)-19 (e.g. into hos ed to last to-day a	(sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (seb	ad sympto been in c ielding) Yes Yes Yes Yes	ontact No ore No one No No No
3. 4. 5.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela Do you currently think you h Do you have any physical or (excluding any long-lasting (<u>If yes</u> : (a) Do any of your co Pse, a Have you ever smoked ciga	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci nave symptor or mental hea COVID-19 sy onditions or ill a lot arettes regula vape at all?	ploms of COVID-1 no has/has had syn aving had an incree el abroad) ing your risk of gett ms consistent with lth conditions or ill inconsistent with lth conditions or ill imptoms)? Inesses reduce yoo _Yes, a little rfy?	9 or a po nptoms o ased risk ting COVI COVID-1 nesses la ur ability	sitive ter r a posit of gettin D-19 (e. 9 infect asting or to carry- Not at	st ive test, g COVIE g, going ion? expecte out day- all	but you h)-19 (e.g. into hos ed to last	(abm) so the prices and the prices a	ad sympto been in c ielding) Yes ths or mo Yes ? (<u>select o</u>	ontact No ore No one No No No
3. 4. 5.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Do you currently think you h Do you currently think you h Have you ever smoked ciga Do you currently smoke or v	ing due to CC ave had symp a someone wh ated to you ha ning after trava ated to reduci nave symptor for mental hea COVID-19 sy onditions or ill a lot arettes regula vape at all?	ploms of COVID-1 no has/has had syn aving had an incree el abroad) ing your risk of gett ms consistent with lth conditions or ill inconsistent with lth conditions or ill imptoms)? Inesses reduce yoo _Yes, a little rfy?	9 or a por nptoms o ased risk ting COVI COVID-1 nesses la ur ability	sitive tes r a posit of gettin D-19 (e. 9 infect asting or to carry- Not at Not at	st ive test, g COVIE g, going ion? expecte out day- all pe/e- cig	but you h)-19 (e.g. into hos ed to last to-day a	(sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (sebmi)sentr (seb	ad sympto been in c ielding) Yes Yes Yes Yes	ontact No ore No one No No No
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Do you currently think you h Do you currently think you h Do you currently think you no (#zeci (a) Do any of your co Yes, a Have you ever smoked ciga Do you currently smoke of any <i>ff yes</i> : (a) please tick all that	ing due to CC ave had symp as comeone wh ated to you ha ning after trava- tated to reduci ave symptor or mental hea COVID-19 s nonditions or ill a lot arettes regula vape at all? C: COI	ptoms of COVID-1 no has/has had sym aving had an increa vel abroad) ing your risk of gett ns consistent with ith conditions or ill mptoms)? Inesses reduce yo Pes, a little rity? igarettesCigar NTACT WITH	9 or a por nptoms o ased risk ting COVID-1 nesses la ur ability Pipe OTHE	sitive ter r a posit of gettin D-19 (e. 9 infect asting or to carry- Not at Not at Va R PEC	st ive test, g COVIE g. going ion? expecte out day- all pe/e- cig PLE	but you h)-19 (e.g. into hos ed to last to-day a jarettes	(Benjaso By/ Ch April 23, 2024	aad sympto been in c ielding) Yes Yes Yes Yes Yes Yes ah/shisha	 No No No No No No a pipes
3. 4. 5. 6.	Are you currently self-isolatii Ves because you have/ha Yes because you live with yourself Yes, for other reasons rela bo you currently think you h 0 you have any physical oi (excluding any long-lasting oi <u>// yes;</u> (a) Do any of your coi Carl yes; (a) please tick all that bo you currently smoke or w <u>// yes;</u> (a) please tick all that In the last 28 days, have you	ing due to CC ave had symp is omeone wh ated to you his ning after trav- ated to reduci nave symptor or mental hea COVID-19 sy onditions or ill a to arettes regula arettes regula dapply: CCO CCO u been in diri	ptoms of COVID-1 on has/has had sym aving had an increa el abroad) ing your risk of gett ms consistent with the conditions or ill ymptoms)? Inesses reduce you yes, a little urtly? igarettesCigar VTACT VVITH ect contact, in pers	9 or a poon mptoms of ased risk ing COVI COVID-1 nesses la ur ability Pipe OTHE son, with	sitive tes r a posit of gettin D-19 (e. 9 infect asting or to carry- Not at Not at Va R PEC someon	st ive test, g COVIE g. going ion? expecte out day- all pe/e- cig PLE e that yo	but you h)-19 (e.g. into hos ed to last to-day a jarettes pu <u>definit</u>	(Bect) (Bomjacon 1 / Op) Amor Amor Kanon Amor Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon	ad sympto been in c ielding) Yes this or mo Yes ? (select o Yes ah/shisha	 No No No No No No a pipes
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela Do you currently think you h Do you have any physical of (<i>tryse</i> ; (a) Do any of your co (excluding any long-lasting (<i>tryse</i> ; (a) please tick all that Do you currently smoke or v <i>tryse</i> ; (a) please tick all that In the last 28 days, have you had a positive test result, wa	ing due to CC ave had symp someone wh ated to you ha ning after trav- ated to reduci- nave symptor or mental hea COVID-19 sy onditions or ill a to arettes regula vape at all? t apply: _C C COI u been in diru as infected w	ptoms of COVID-1 on has/has had sym aving had an increa el abroad) ing your risk of gett ing your risk of gett	9 or a poon mptoms of ased risk ing COVID-1 nesses la ur ability Pipe OTHEI son, with he time y	sitive ter r a posit of gettin D-19 (e. 9 infect asting or to carry- Not at Va Va Someon ou were	st ive test, g COVIE g. going on? expecte out day- all pe/e- cig PLE e that yo in conta	but you h)-19 (e.g. into hos ed to last to-day a jarettes pu <u>definit</u>	(Bect) (Bomjacon 1 / Op) Amor Amor Kanon Amor Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon Kanon	ad sympto been in c ielding) Yes this or mo Yes ? (select o Yes ah/shisha	 No No No No No No a pipes
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Do you currently think you h Do you currently think you h Do you currently think you h Quescluding any long-lasting (<u>fyes:</u> (a) Do any of your co Yes: (a) Do any of your co Yes: (a) please tick all that In the last 28 days, have you had a positive test result, wa <u>ffyes:</u> (a) Date of last contact	ing due to CC ave had symp is someone with atact to you hit ning after trav- atact to reduci atact to reduci atave symptor are symptor or mental hea COVID-19 sy norditions or ill a lot arattes regula vape at all? It apply: CC CC CC CC CC CC CC CC CC CC CC CC CC	ptoms of COVID-1 on has/has had sym aving had an increa (e) abroad) ing your risk of gett ins consistent with lift conditions or ill messes reduce yo Pes, a little mypoms)? Inesses reduce yo Pes, a little rity? Cigar ett contact, in perset ett contact, in perset it COVID-19 at ti e:	9 or a por mptoms o ased risk ting COVI COVID-1 nesses la ur ability 	sitive ter r a positi of gettin D-19 (e. 9 infect asting or to carry- Not al Va R PEO someon ou were <u>M</u> 2	st ive test, g COVIE g. going ion? expecte out day- all pe/e- cig PLE e that yo in conta 0 2 7	but you h)-19 (e.g. into hos ed to last to-day a garettes pu <u>definit</u>	(建bmj柔on)/如April 223, 20之4)发夏ue	ad sympto been in c ielding) Yes Yes ? (select o Yes Yes cah/shisha w, becaus	ontact No No No No Se they No
3. 4. 5. 6.	Are you currently self-isolatii Ves because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Do you currently think you h Do you currently think you h Do you currently think you h Do you currently think you n O you currently smoked or <u>If yes</u> : (a) please tick all that In the last 28 days, have you had a positive test result, wa (b) Was this last pers-	ing due to CC ave had sympt a someone wh ated to you ha ning after trav- ated to reduci ated to reduci are symptor. The sympt sector or mental hea COVID-19 sy noritions or ill a lot a lot a regular vape at all? C: COI u been in diri as infected w uch of this typp son you had t	ptoms of COVID-1 no has/has had sym aving had an increa el abroad) ing your risk of gett ms consistent with the conditions or ill mptoms)? Inesses reduce you Inesses reduce you Insesses	9 or a por mptoms o ased risk ting COVI COVID-1 nesses la ur ability "Pipe OTHEE son, with he time y	sitive te: r a position of gettin D-19 (e. 9 infect asting or to carry- Not at Va R PEC someon ou were M 2 living ir	st ive test, g COVIE g. going ion? expecte out day- all pe/e- cig PLE e that your in conta 0 2 7	but you h)-19 (e.g. into hos ed to last to-day a garettes ou <u>definit</u> act with t	(過bm) 森の潮/ 頭) Apriliz23, 20之の疑慮のuest	ad sympto been in c ielding) Yes this or mo Yes ? (select o Yes ah/shisha w, becaus Yes side your	ontact No No No No Se they No
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela bo you currently think you ho you currently think you ho you ave any physical or (excluding any long-lasting or <u>f' yes</u> : (a) Do any of your co <u>yes</u> , a Have you ever smoked ciga Do you currently smoke or w <u>f' yes</u> : (a) please tick all that In the last 28 days, have you had a positive test result, was (b) Was this last pers In the last 28 days, have you had say the last 28 days, have you had a sotil test result, was <u>f' yes</u> : (a) Date of last contar- (b) Was this last pers In the last 28 days, have you	ing due to CC ave had symp is omeone wh ated to you hi ning after trav- ated to reduci- nave symptor or mental hea COVID-19 sy onditions or ill a to arettes regula arettes regula arettes regula arettes regula tapply: CCOD u been in diri as infected w ct of this type son you had t u been in diri son you had t	ptoms of COVID-1 on has/has had sym aving had an increa el abroad) ing your risk of gett ns consistent with this conditions or ill ymptoms)? Inesses reduce you ymptoms)? Inesses reduce you y	9 or a por mptoms o ased risk ting COVID-1 nesses la ur ability Pipe OTHEE son, with he time y with son, with son, with	sitive ter r a posit of gettin D-19 (e. 9 infect asting or to carry- Not at Va R PEO someon ou were M 2 M 2	st ive test, g COVIE g. going expecte out day- all pe/e- cig PLE e that yo in control 0 2 0 your ov e that yo	but you h -19 (e.g. into hos ed to last to-day a garettes bu <u>definit</u> act with t with nome bu <u>think</u> v	(記bm) 梁の 溜/ (京) April [[23], 2024) 送 圓 uest, we may a start with the start we may a start we	ad sympto been in c ielding) Yes Yes ? (select c Yes ah/shisha W becaus Side your cted with	ontact Ore No Ore No Ore No Ore No No ore No No ore No No home
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Do you currently think you h Do you currently smoke or u <u>If yes</u> : (a) De any of your co Do you currently smoke or u <u>If yes</u> : (a) please tick all that in the last 28 days, have you had a positive test result, we <u>If yes</u> : (a) Date of last contat (b) Was this last person In the last 28 days, have you COVID-19 at the time you your solution (b) Was this last person In the last 28 days, have you (b) Was this last person In the last 28 days, have you have you have you had a positive test result, we (b) Was this last person In the last 28 days, have you have you have you had a positive test result, we (b) Was this last person In the last 28 days, have you	ing due to CC ave had symp a someone with ated to you hi ning after trav- ated to reduci ave symptor COVID-19 sy norditions or II a lot arettes regula vape at all? It apply:C CC COI U u been in din as infected wich stype son you had t u been in din were in conta	ptoms of COVID-1 on has/has had sym aving had an increa (e) abroad) ing your risk of gett ms consistent with this conditions or ill ymptoms)? Inesses reduce yoo Pes, a little rith? Cigar thy? Cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigarettes cigare	9 or a point of the point of th	sitive ter r a positi of gettin D-19 (e 9 infect issting or to carry- Not at Va Va R PEC Someon ou were M 2 i living ir someon clude: s	st ive test, g COVIE g, going on? expecte out day: all pe/e- cig PLE e that you in control your ow e that you comeone	but you h)-19 (e.g. into hosp ed to last to-day a parettes pu <u>definit</u> act with t wn home you <u>think</u> you think you	(動) (動) (動) (動) (動) (動) (動) (動)	and sympto been in c ielding) Yes Yes Yes ah/shisha Yes side your ccted with	 No No No No No a pipes se they No home
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Do you currently think you h Do you currently think you h Do you currently think you h Do you currently think you n May so any of your co Yes; (a) Do any of your co Yes; (a) please tick all that In the last 28 days, have you had a positive test result, wa <i>If yes</i> : (a) Date of last contar (b) Was this last persi In the last 28 days, have you someone who has been test	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot a control of the second of this type son you had to u been in dirit as infected we son you had to u been in dirit as infected we son you had to u been in dirit as infected we son you had to u been in dirit as infected we	ptoms of COVID-1 no has/has had sym aving had an increa el abroad) mg your risk of gett ms consistent with lth conditions or ill mptoms)? Inesses reduce yo msses reduce yo ray a little rity? Itact WITH et contact, in pers th COVID-19 at tt s: his type of contact et contact, in pers to dwith them — this to not know the re:	9 or a point of the point of th	sitive ter r a positi of gettin D-19 (e 9 infect asting or to carry- Not al Va Va R PEC Someon ou were M 2 living i living or curve- meone	st ive test, g COVIE g, going expecte out day- all pe/e- cig pe/e- ci	but you h)-19 (e.g. into hosp ed to last to-day a parettes pu <u>definit</u> act with t wn home you <u>think</u> you think you	(動) (動) (動) (動) (動) (動) (動) (動)	and sympto been in c ielding) Yes Yes Yes ah/shisha Yes side your ccted with	ontact Ore No Ore No Ore No Ore No No ore No No ore No No home
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Do you currently think you h Do you currently smoke or u <u>If yes</u> : (a) De any of your co Do you currently smoke or u <u>If yes</u> : (a) please tick all that in the last 28 days, have you had a positive test result, we <u>If yes</u> : (a) Date of last contat (b) Was this last person In the last 28 days, have you COVID-19 at the time you your solution (b) Was this last person In the last 28 days, have you (b) Was this last person In the last 28 days, have you have you have you had a positive test result, we (b) Was this last person In the last 28 days, have you have you have you had a positive test result, we (b) Was this last person (b) W	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot a control of the second of this type son you had to u been in dirit as infected we son you had to u been in dirit as infected we son you had to u been in dirit as infected we son you had to u been in dirit as infected we	ptoms of COVID-1 no has/has had sym aving had an increa el abroad) mg your risk of gett ms consistent with lth conditions or ill mptoms)? Inesses reduce yo msses reduce yo ray a little rity? Itact WITH et contact, in pers th COVID-19 at tt s: his type of contact et contact, in pers to dwith them — this to not know the re:	9 or a point of the point of th	sitive ter r a positi of gettin D-19 (e 9 infect asting or to carry- Not al Va Va R PEC Someon ou were M 2 living i living or curve- mene	st ive test, g COVIE g, going expecte out day- all pe/e- cig pe/e- ci	but you h)-19 (e.g. into hosp ed to last to-day a parettes pu <u>definit</u> act with t wn home you <u>think</u> you think you	(動) (動) (動) (動) (動) (動) (動) (動)	and sympto been in c ielding) Yes Yes Yes ah/shisha Yes side your ccted with	 No No No No No a pipes se they No home
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Do you currently think you h Do you currently think you h Do you currently think you h Do you currently think you n May so any of your co Yes; (a) Do any of your co Yes; (a) please tick all that In the last 28 days, have you had a positive test result, wa <i>If yes</i> : (a) Date of last contar (b) Was this last persi In the last 28 days, have you someone who has been test	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ated to reduci are symptor. The symptox of all a lot a lot a covid-19 symptox or mental hea COVID-19 sy norditions or ill a lot a lot a regular version of all a lot a regular version of all a lot a lot a regular version of all a lot a lo	ptoms of COVID-1 no has/has had sym aving had an increa el abroad) ing your risk of gett ms consistent with this conditions or iil mptoms)? Inesses reduce you /res, a little myty? iigarettes Cigar XITACTWITH ect contact, in pers tht COVID-19 at tt a: a contact, in pers act with them – this to not know the reise a:	9 or a poon assed risk of assess as a result of assess of a result of a result of assess of a result of a result of assess of a result of assess of a result of assess of a result of a result of assess of a result of a re	sitive ter r a positi of gettin D-19 (e gettin D-19 (e	st g COVIE g going expecte out day- all pe/e- cig pe/e- cig	but you h -19 (e.g. into hos; ad to last to-day a garettes yarettes yarettes yarettes bu <u>definit</u> act with th set to hos; yarettes act with th yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes yarettes	(動) 動) 動) 動 動 動 し し し し し し し し し し し し し	and sympton been in c ielding) Yes this or mc Yes (select of Yes an/shisha Yes Side your ccted with en tested; ? Yes	 No No No No No a pipes se they No home No
3. 4. 5. 6.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Yes, for other reasons rela with a known case, quarantii Yes, for other reasons rela with a known case, quarantii Yes, for other reasons rela with a known case, quarantii Yes, (a) Do any of your co Yes, a Have you ever smoked ciga Do you currently smoke or v <i>If yes:</i> (a) please tick all that In the last 28 days, have you had a positive test result, wa <i>If yes:</i> (a) Date of last contaar (b) Was this last perso In the last 28 days, have you someone who has been test <i>If yes:</i> (a) Date of last contaar (b) Was this last perso In the last 28 days, have you Someone who has been test (b) Was this last perso In the last 28 days, have you ColvID-19 at the time you y Someone who has been test (b) Was this last perso In the last 28 days, have you (b) Was this last perso In the last 28 days, have you (b) Was this last perso In the last 28 days, have you (b) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso (c	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot arettes regula vape at all? CCCC CCCC CCCC CCCCC CCCCC CCCCC CCCCCC	ptoms of COVID-1 on has/has had sym aving had an increa el abroad) ing your risk of gett ns consistent with this conditions or ill ymptoms)? Inesses reduce you yes, a little urly? Inesses reduce yes, a little urly? Inesses reduce	9 or a por nptoms o ased risk ting COVI COVID-1 nesses la ur ability Pipe OTHEE son, with the time y with	sitive ter a posit of gettin D-19 (e, 9 infect ststing or to carry: Not al Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa V	st ive test, g COVIE g going expecte out day- all pe/e- cig pe/e-	but you h -19 (e.g. into hoss into hoss is tested in into hoss into hoss into hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho ho	abom jero たいのでは、またので、またので、またので、またので、またので、またので、またので、またので	and symple been in c ielding) Yes (select of Yes (select of Yes ah/shisha yes side your ccted with en tested; ? Yes side your or treatme	No re No No No No No No pipes ethey No home
3. 4. 5. 6. 1. 2.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, (a) bo any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) please tick all that In the last 28 days, have you had a positive test result, wa If yes: (a) Date of last contar (b) Was this last person In the last 28 days, have you someone who has been test If yes: (a) Date of last contar (b) Was this last person (b) Was this last person (c) W	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot arettes regula vape at all? CCCC CCCC CCCC CCCCC CCCCC CCCCC CCCCCC	ptoms of COVID-1 no has/has had syn aving had an increa el abroad) ing your risk of gett ns consistent with ith conditions or ill mptoms)? Inesses reduce yo Ps, a little rity? igarettesCigar TACT WITH ect contact, in pers th COVID-19 at tl s: his type of contact ect contact, mers s: his type of contact e a hospital for any mers	9 or a poor phytoms o assed risk ing COVID-1 nesses la COVID-1 nesses la ur ability Pipe OTHE OTHE OTHE or, with he time y with with reason (reason (sitive ter a posit of gettin D-19 (e, 9 infect ststing or to carry: Not al Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa V	st ive test, g COVIE g going expecte out day- all pe/e- cig pe/e-	but you h -19 (e.g. into hoss into hoss is tested in into hoss into hoss into hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho ho	abom jero たいのでは、またので、またので、またので、またので、またので、またので、またので、またので	and symple been in c ielding) Yes (select of Yes (select of Yes anh/shisho Yes side your ccted with en tested; Yes side your or treatme Yes	No re No No No No No pipes e they No home home
3. 4. 5. 6. 1. 2.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantii Yes, for other reasons rela with a known case, quarantii Yes, for other reasons rela with a known case, quarantii Yes, for other reasons rela with a known case, quarantii Yes, (a) Do any of your co Yes, a Have you ever smoked ciga Do you currently smoke or v <i>If yes:</i> (a) please tick all that In the last 28 days, have you had a positive test result, wa <i>If yes:</i> (a) Date of last contaar (b) Was this last perso In the last 28 days, have you someone who has been test <i>If yes:</i> (a) Date of last contaar (b) Was this last perso In the last 28 days, have you Someone who has been test (b) Was this last perso In the last 28 days, have you ColvID-19 at the time you y Someone who has been test (b) Was this last perso In the last 28 days, have you (b) Was this last perso In the last 28 days, have you (b) Was this last perso In the last 28 days, have you (b) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso In the last 28 days, have you (c) Was this last perso (c	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot arettes regula vape at all? CCCC CCCC CCCC CCCCC CCCCC CCCCC CCCCCC	ptoms of COVID-1 on has/has had sym aving had an increa el abroad) ing your risk of gett ns consistent with this conditions or ill ymptoms)? Inesses reduce you yes, a little urly? Inesses reduce yes, a little urly? Inesses reduce	9 or a poor phytoms o assed risk ing COVID-1 nesses la COVID-1 nesses la ur ability Pipe OTHE OTHE OTHE or, with he time y with with reason (reason (sitive ter a posit of gettin D-19 (e, 9 infect ststing or to carry: Not al Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa V	st ive test, g COVIE g going expecte out day- all pe/e- cig pe/e-	but you h -19 (e.g. into hoss into hoss is tested in into hoss into hoss into hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho ho	いたいです。 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「、 「、 「、 「、 「、 「、 「、 「、 「、 「、	and symple been in c ielding) Yes (select of Yes (select of Yes anh/shisho Yes side your ccted with en tested; Yes side your or treatme Yes	No re No No No No No No pipes ethey No home
3. 4. 5. 6. 1. 2.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, (a) bo any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) please tick all that In the last 28 days, have you had a positive test result, wa If yes: (a) Date of last contar (b) Was this last person In the last 28 days, have you someone who has been test If yes: (a) Date of last contar (b) Was this last person (b) Was this last person (c) W	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot arettes regula vape at all? CCCC CCCC CCCC CCCCC CCCCC CCCCC CCCCCC	ptoms of COVID-1 no has/has had syn aving had an increa el abroad) ing your risk of gett ns consistent with ith conditions or ill mptoms)? Inesses reduce yo Ps, a little rity? igarettesCigar TACT WITH ect contact, in pers th COVID-19 at tl s: his type of contact et with them — this to not know the res s: his type of contact e a hospital for any	9 or a poor phytoms o assed risk ing COVID-1 nesses la COVID-1 nesses la ur ability Pipe OTHE OTHE OTHE or, with he time y with with reason (reason (sitive ter a posit of gettin D-19 (e, 9 infect ststing or to carry: Not al Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa V	st ive test, g COVIE g going expecte out day- all pe/e- cig pe/e-	but you h -19 (e.g. into hoss into hoss is tested in into hoss into hoss into hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho ho	いたいです。 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「、 「、 「、 「、 「、 「、 「、 「、 「、 「、	and symple been in c ielding) Yes (select of Yes (select of Yes anh/shisho Yes side your ccted with en tested; Yes side your or treatme Yes	No re No No No No No pipes e they No home home
3. 4. 5. 6. 1. 2.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, (a) bo any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) please tick all that In the last 28 days, have you had a positive test result, wa If yes: (a) Date of last contar (b) Was this last person In the last 28 days, have you someone who has been test If yes: (a) Date of last contar (b) Was this last person (b) Was this last person (c) W	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot arettes regula vape at all? CCCC CCCC CCCC CCCCC CCCCC CCCCC CCCCCC	ptoms of COVID-1 no has/has had syn aving had an increa el abroad) ing your risk of gett ns consistent with ith conditions or ill mptoms)? Inesses reduce yo Ps, a little rity? igarettesCigar TACT WITH ect contact, in pers th COVID-19 at tl s: his type of contact et with them — this to not know the res s: his type of contact e a hospital for any	9 or a poor phytoms o assed risk ing COVID-1 nesses la COVID-1 nesses la ur ability Pipe OTHE OTHE OTHE or, with he time y with with reason (reason (sitive ter a posit of gettin D-19 (e, 9 infect ststing or to carry: Not al Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa V	st ive test, g COVIE g going expecte out day- all pe/e- cig pe/e-	but you h -19 (e.g. into hoss into hoss is tested in into hoss into hoss into hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho ho	いたいです。 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「、 「、 「、 「、 「、 「、 「、 「、 「、 「、	and symple been in c ielding) Yes (select of Yes (select of Yes anh/shisho Yes side your ccted with en tested; Yes side your or treatme Yes	No re No No No No No pipes e they No home home
3. 4. 5. 6. 1. 2.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, (a) bo any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) please tick all that In the last 28 days, have you had a positive test result, wa If yes: (a) Date of last contar (b) Was this last person In the last 28 days, have you someone who has been test If yes: (a) Date of last contar (b) Was this last person (b) Was this last person (c) W	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot arettes regula vape at all? CCCC CCCC CCCC CCCCC CCCCC CCCCC CCCCCC	ptoms of COVID-1 no has/has had syn aving had an increa el abroad) ing your risk of gett ns consistent with ith conditions or ill mptoms)? Inesses reduce yo Ps, a little rity? igarettesCigar TACT WITH ect contact, in pers th COVID-19 at tl s: his type of contact et with them — this to not know the res s: his type of contact e a hospital for any	9 or a poor phytoms o assed risk ing COVID-1 nesses la COVID-1 nesses la ur ability Pipe OTHE OTHE OTHE or, with he time y with with reason (reason (sitive ter a posit of gettin D-19 (e, 9 infect ststing or to carry: Not al Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa V	st ive test, g COVIE g going expecte out day- all pe/e- cig pe/e-	but you h -19 (e.g. into hoss into hoss is tested in into hoss into hoss into hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho ho	abom jero たいのでは、またので、またので、またので、またので、またので、またので、またので、またので	and symple been in c ielding) Yes (select of Yes (select of Yes anh/shisho Yes side your ccted with en tested; Yes side your or treatme Yes	No re No No No No No pipes e they No home home
3. 4. 5. 6. 1. 2.	Are you currently self-isolatii No Yes because you have/ha Yes because you live with yourself Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, for other reasons rela with a known case, quarantir Yes, (a) bo any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) Do any of your co Yes, (a) please tick all that In the last 28 days, have you had a positive test result, wa If yes: (a) Date of last contar (b) Was this last person In the last 28 days, have you someone who has been test If yes: (a) Date of last contar (b) Was this last person (b) Was this last person (c) W	ing due to CC ave had symp a someone wh ated to you ha ning after trav- ated to reduci ave symptor or mental hea COVID-19 sy norditions or ill a lot arettes regula vape at all? CCCC CCCC CCCC CCCCC CCCCC CCCCC CCCCCC	ptoms of COVID-1 no has/has had syn aving had an increa el abroad) ing your risk of gett ns consistent with ith conditions or ill mptoms)? Inesses reduce yo Ps, a little rity? igarettesCigar TACT WITH ect contact, in pers th COVID-19 at tl s: his type of contact et with them — this to not know the res s: his type of contact e a hospital for any	9 or a poor phytoms o assed risk ing COVID-1 nesses la COVID-1 nesses la ur ability Pipe OTHE OTHE OTHE or, with he time y with with reason (reason (sitive ter a posit of gettin D-19 (e, 9 infect ststing or to carry: Not al Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa Vaa V	st ive test, g COVIE g going expecte out day- all pe/e- cig pe/e-	but you h -19 (e.g. into hoss into hoss is tested in into hoss into hoss into hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho hoss is tested in into hoss is tho hoss is tested in into hoss is tested in into hoss is tho ho	いたいです。 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」では、 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「たい」 「、 「、 「、 「、 「、 「、 「、 「、 「、 「、	and symple been in c ielding) Yes (select of Yes (select of Yes anh/shisho Yes side your ccted with en tested; Yes side your or treatme Yes	No re No No No No No pipes e they No home home

bmjopen-2021-054200

Control with the last 7 days, here many difference of your block products with the generation of the last 7 days, here many difference of the last 7 days,		021
<form></form>		Ģ
<form></form>		54
<form></form>		
In the state 2.22 state, how may be apprecised with a service be direct or the service be		ŏ
In the constraintion of build someone (b) table someone check) In the constraintion of th	If no: (a) In the last 28 days, has anyone that you usually live with been inside a hospital at all for any reason (e.g.	If yes: (a) What was the result/were the results of all tests you've had since we last spoke to you?
4. the fact 20 day, have you been table a carefused with all of the only you been table a carefused with all sources to the sources to the source with the sources of the sources to the sources of the sources		 One or more positive test(s) One or more negative tests, but none
The set is the set of the seto		All tests failed Waiting for all results
with, is visit someone, Is the sameone energy		we last spoke to you?
For the last 7 days, from many functions adop on average have you speet within 2 of someone else my cut in the last 7 days, from many other add data data data data data data data		we lest apply to you?
Control length delegangy <td></td> <td>3. If yes to Q2: had a swab test of your nose and throat to test for COVID-19 infection. Are you remaining the</td>		3. If yes to Q2: had a swab test of your nose and throat to test for COVID-19 infection. Are you remaining the
core the last 7 days, here mark data field or estimating with FPE # you were fit (which can be adding the physical contact with (e.g. threads a general can), including with FPE # you were fit (which can be adding the physical contact with (e.g. threads a general can), including with FPE # you were fit (which can be adding the physical contact with (e.g. threads a general can), including with FPE # you were fit (which can be adding the physical contact with (e.g. threads a general can), including with FPE # you were fit (which can be adding the physical contact with (e.g. threads a general can), including with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding with FPE # you were fit (which can be adding the physical contact with (e.g. threads a thread to be adding the physical contact with the physical contact wit		for COVID-19 using a lateral flow test: that's the test you can do yourself and you do not have to send it to
A control table of days, how many data 1560 or table of datal 1560 or table of data	 Over the last 7 days, how many <u>children and young adults <18</u> y not living in your home have you had physical accurate with (a paradebia parameter and young adults <u><18</u>) fit your paradebia. 	because the result shows in the device in about 30 minutes?
7. Doer the saf 7 days, how many data 1.680 mot long hand bing for a contact with (e.g.) and hand hand or the region to have push that physical contact with (e.g.) and hand hand with FFE 7 posses with 7 deep data for more particular sets (f. addit contact with (e.g.) and hand hand with FFE 7 posses with 7 deep data for more particular sets (f. addit contact with (e.g.) and hand hand with FFE 7 posses with 7 deep data for more particular sets (f. addit contact with (e.g.) and hand hand with FFE 7 posses with 7 deep data for more particular sets (f. addit contact with (e.g.) and hand hand with FFE 7 posses with 7 deep data for more particular sets (f. addit contact with (e.g.) and hand hand with FFE 7 posses with 7 deep data for more particular sets (f. addit contact with (e.g.) and hand hand for the many physical contact with a posses of a deta for posses for more particular sets (f. addit contact with (e.g.) and hand hand for the many physical contact with posses (f. addit contact with (e.g.) and hand hand for the many physical contact with posses (f. addit contact with posses, e.g. with scale data for posses for more particular sets (f. addit data for posses for more particular sets (f. addit data for posses for posses for more for more for more for more for posses for more	contact with (e.g. nanosnake, personal care), including with PPE if you wear it? (select one)	4. Have you had a blood test to test for COVID-19 antibodies since we last spoke to you (not in willing a
Inheritable, personal cred, including with PEE Tops weart (P calebo cole) 10 12 12 or meth list 37 days, how many clead 2000 or most personal cred, including with PEE Tops weart (P calebo cole) 12 or meth list 37 days, how many clead 2000 or most personal cred, including with PEE Tops weart (P calebo cole) 12 or most personal cred, including with PEE Tops weart (P calebo cole) 13 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 <td></td> <td>as part of this study)?</td>		as part of this study)?
Benefit the last 7 days, how many default and your home have you had physical contact with (eg. handball, with PE if your home have you had contact with (eg. handball, contact with (eg	handshake, personal care), including with PPE if you wear it? (select one)	It yes: (a) What was the result/were the results of all tests you've had since we last spoke to you? (see
a. Core the start age, how many chart and your bar file with your bar how the your bar file age with a physical contract with a person, a give show the your bar file age with social distances give (see your bar file age). The start age, how many chart age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with social distances give (see your bar file age). The start age with age w		
Cover the last 7 days, how many <u>different and yourn addition</u> 11:20 12.0 run mee physical, contact with n person, e.g. with social distancing only (select and) (b) cell the last 7 days, how many <u>different and yourn addition</u> 11:20 12.0 run mee (b) and you describe yournel addition the different of the last 7 days, how many <u>different and yourn addition</u> 15 1 12 0 12.0 run mee (b) and you describe yournel addition the different of the last 7 days, how many <u>different and yournel</u> addition (c) and you how you how how you have have you had direct, but not physical, contact with n person, e.g. with social distancing only (select and) (b) or the last 7 days, how many <u>different and yournel</u> have you had direct, but not physical, contact with n person, e.g. with social distancing only (select and) (b) or the last 7 days, how many times have you seen or to the yournel have you had direct, but not physical, contact with n person, e.g. with social distancing only (select and) (b) or the last 7 days, how many times have you seen or to the yournel have you had direct, but not (b) or the last 7 days, how many times have you seen or to the yournel have you had direct, but not (b) how many times have you been or different mode (b) how many times have you been or different mode (b) how many times have you been or different mode (b) how many times have you been or different mode (b) how many times have you been or different mode (b) how many times have you been or different mode (b) how many times have you been or different mode (b) how many times have you have or different mode (b) how many times have you have or different mode (b) how many times have you have or different mode (b) how many times have you have or different mode (b) how many times have you have or different mode (b) how many times have you have or different mode (b) how many times have you have or different mode (b) how		(b) Where was the test done? (if more than one test, provide for the most recent positive test,
Control is a control in the list of days, how many children and young skills -16 yn thing in your home have you had direct, but not physical, contact with in person, e.g. with social distancing only (delet days) in the dect, but not physical, contact with in person, e.g. with social distancing only (delet days) in the dect, but not physical, contact with in person, e.g. with social distancing only (delet days) in the dect, but not physical, contact with in person, e.g. with social distancing only (delet days) in the dect, but not physical, contact with in person, e.g. with social distancing only (delet days) in the list of days, how many udelet adjust in the days of the building of another person's in the days of the building of another person's in the days of the building of another person's in the days of the building of another person's in the days of the building of another person's in the days of the building of another person's in the days of the days, how many under days in the width our generative building of another person's in the days, how many under days of the days of the width our generative building of another person's in the days of the days o		(sevect one) otherwise the most recent negative test, otherwise the most receil
pripriced, contact with in person, 6.g. with social distancing only? (leaded only 10 or we the sit of this private, contact with in person, 6.g. with social distancing only? (leaded only 10 or we the sit of this private, contact with in person, 6.g. with social distancing only? (leaded only 10 Or we the sit of this person, 6.g. with social distancing only? (leaded only 10 or leaded bit in person, 6.g. with social distancing only? (leaded only 11 Or we the list 7 days, how many tokes added Sign on only person in south the list of days, how many tokes at position on or longer inside the buildings of another person's contact with in person, 6.g. with social distancing only? (leaded only on the list of days, how many times thas someon who doesn't live with our spent on the our or longer inside the buildings of another person's contact with in person, 6.g. with social distancing only? (leaded only on the list of days, how many times thas someon who doesn't live with our spent on the our or longer inside the buildings of another person's contact with person and the list of days, how many times thas someon who doesn't live with our spent on the our or longer inside the buildings of another person's contact with person and without person and a	9. Over the last 7 days, how many children and young adults <18y not living in your home have you had direct, but not	(c) <u>if any lest positive</u> , what was the date of hist positive test you ve had since
10 Over the last 7 days, how many data! 1:8:5:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0		we last spoke to you?
with in person, e.g. with social distancing only (select one) 0 1.5 6-10 11-20 21 or more 11. Over the last 7 days, how many idea gallst 200 and own ont king in you home have you had dired, but not physics, or only with lable 20 and you with lable 20 and you have have you had be used with lables 200, with lable 20 and you have have you had be used with lables 200, with lable 20 and you have have you had be used with lables 200, with lable 20 and you have have you had be used with lables 200, with lable 20 and you have have you had be used with lables 200, with lable 20 and you have have you have you have have you have have you have have y		we last spoke to you?
11. Our the list 7 days, how many lotier guilty 10 and over not living in your home have you had dired, but not physical, cortact with presson, guilts scale compared with living in your home have you had dired, but not physical, cortact with presson, guilts scale dired have any dired data with living have your home hour or longer inside the buildings of your home? Effect (1) and (with in person, e.g. with social distancing only? (select one)	If week 4 or later. Would you describe yourself as having "long COVID", that is, you are still experience
physical, cordat with person, e.g. with social distancing only (select one) 0 14. In the last 7 days, how may times have you spent one hour onlogar inside the buildings of another person's 2. In the last 7 days, how may times have you spent one hour onlogar inside the buildings of another person's COVID-197 (select one) None 19. Do the last 7 days, how may times have you ben observit with you gene to hour or torgar inside the buildings of another person's Do by to ubservit with long COVID has made worse (answer Yes or No for edge none 13. In the last 7 days, how may times have you ben observit with you gene to hour or torgar inside the buildings of another person's times or more None 10. Do you have you have on the our or board in with you gene to hour or torgar inside the buildings of another person's times or more None 10. Do you have you have on the our or board in with you gene to hour or torgar inside the buildings of another person's times or more None 10. Do you have you have on the our or board in with you have person because of COVID-16 you have you are at work/your place of education, because of COVID-16 you have any hard of face covering or mask when you are at work/your place of education, because of COVID-16 you have any hard of face covering or mask when you are at work/your place of education because of COVID-16 you have any hard of accoursent or note when you have any hard of accoursent or note when you have any hard of accoursent or note when you have at work/your place of education, because of COVID-16 you have a make on the you have any hard of accoursent or calcular teasons) No 10. Do you have or think you have conneigh or table and whand you had COVID-19 you have any segntons when you th		more than 4 weeks after you first had COVID-19, that are not explained by something else?
12. In the last 7 days, how many times have you server on hour or longer inside the buildings of our houre? (select care) 13. In the last 7 days, how many times have you server on hour or longer inside the buildings of our houre? (select care) 13. In the last 7 days, how many times have you been outside of your home to socialise, including visiting restaurants, etc? 16. Do you have any that 1 data care in the last 2 days, how many times have you been outside of your home to socialise, including visiting restaurants, etc? 16. Do you warry times have you been outside of your home to socialise, including visiting restaurants, etc? 16. Do you warry times have you been outside of your home to socialise, including visiting restaurants, etc? 16. Do you warry times have you been outside of your home to socialise, including visiting restaurants, etc? 16. Do you warry times have you been outside of your home to socialise, including visiting restaurants, etc? 16. Do you warry times have you been outside of your home to socialise, including visiting restaurants, etc? 16. Do you warry times have you been outside of your home to socialise, including visiting restaurants, etc? 17. Do you warry times have you been outside of your home to socialise, including visiting restaurants, etc? 18. The last 7 days, how many times have you been outside of your home in the enclosed public spaces, such as shops, or ling public transport 19. Do you know or time you have any of the following yniphones the you warry of the following yniphones the you warry of the following yniphones the you warry times and work (associal associal transport) 19. Do you know or time you have any of the following yniphone when you are in othere enclosed public spaces or using public transport		COVID-192 (select one) Ves a lot Ves a little
12. In the last 7 days, how many times have you spent one hour or longer inside the buildings of another person's more In the last 7 days, how many times have sources who beam the buildings of another person's more 13. In the last 7 days, how many times have sources who beam the building of another person's more In the last 7 days, how many times have sources who beam the building setting restarants, etc? 16. In the last 7 days, how many times have you been to socialie, including visiting restarants, etc? Interestarants, etc? 16. In the last 7 days, how many times have you been to socialied. Further to socialies, including visiting restarants, etc? Interestarants, etc? 16. Drove and an int of face covering or mask when you are at work/our place of education. because of COVID-19 including visiting restarants, etc? Note est pain (State Covering or mask when you are at work/our place of education. Because of COVID-19 including visiting restarants, etc? 17. Do you wear any kind face covering or mask when you are at work/our place of education. Because of COVID-19? Note is already covered for other reasons (e.g. religious or cultural reasons) 17. Do you wear any kind face covering or mask when you are at work/our place of education. Because of COVID-19? Note is already covered for other reasons (e.g. religious or cultural reasons) 16. Obj you have any symptoms? Drec COVID-19? Note is already covered for other reasons (e.g. religious or cultural reasons) 17. Do you wear any kind face covering or mask when you have covering or mask wheny you have the subject to you? Note is		
13. In the last 7 days, how many times has someone who desert live with you spent one hour or longer inside the buildings of your home? (select 2002) Inside of your home? (select 2002) None	12. In the last 7 days, how many times have you spent one hour or longer inside the buildings of another person's	pre-existing symptoms which long COVID has made worse (answer Yes or No for each one
Dublings of your hone? (gelect Care) None 1 2 3 4 5 6 7 times or more 14. In the list 7 days, how may times have you been outside of your home to socialize, funding visiting restaurants, etc? Restaurant		
14. In the last 7 days, how many times have you been outside of your home to shopping? (defect care) No Loss of taget Ves No Loss of taget		
15. In the last 7 days, how many times have you been outside of your home to socialise, including visiting restaurants, etc? (select core) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	 In the last 7 days, how many times have you been outside of your home for shopping? (<u>select one</u>) 	
(a) (a) (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c		0
Image: None in image: None in items or more if the symptoms when you are at work/your place order(action, because of COVID-19) (select one) Image: None		
0: 07 (deletion) 0: 0 deletion) 0:	None 1 2 3 4 5 6 7 times or more	
Not going to place of work or education Yes, showays Yes, sometimes In the Newer My face is already covered for other reasons) In the Newer In the Newer In the Newer 17. Do you wear any kind of face covering or mask when you are in other enclosed public spaces, such as shops, or using public transport. In the Newer In the Newer Not going to place to work or education Yes, always Yes, sometimes In the Newer Not going to other enclosed public spaces or using public transport. Yes, always Yes, sometimes In the Newer Ny face is already covered for other reasons (e.g. religious or cultural reasons) In the New Pace and CovinD-199 (select Ore) In the New Pace and CovinD-199 (select Ore) In the New Pace and State Ore) 10. Do you know or think you have had covinD-199 Yes No Yes No Yes No In the New Pace and State Ore New Pace		Memory loss or Difficultly
17. Do you wear any kind of face covering or mask when you are in other enclosed public spaces, such as shops, or using public transport. Leasause of COVID-199 (specied covering or mask when you are in other enclosed public spaces, such as shops, or using public transport. Leasause of COVID-199 (specied covering or mask when you are in other enclosed public spaces, such as shops, or Y es a ways. If no to Qee: (a) Have you been offered a vaccination against COVID-19 since we last spoke to you? If no to Qee: (a) Have you been offered a vaccination against COVID-19 since we last spoke to you? If no to Qee: (b) Type of vaccination (specied covering or mask when you have had coronavirus (COVID-19) since we last spoke to you? (If not sure, select No) 17. Do you know or think you have had coronavirus (COVID-19) since we last spoke to you? (If not sure, select No) Y es to Qe: (b) Type of vaccination (specied covering or mask when you have any symptoms when you have or thought you had COVID-19? Yes No (c) Did you have any symptoms when you knew or thought you had COVID-19? Yes No No (c) Urge; (b) Jup ou have any of the following symptoms? (answer Yes or No for each one) Yes No No (d) Did you contact the NHS when you thought you had COVID-19? Yes No No (d) Did you contact the NHS when you thought you had COVID-19? Yes No No (d) Did you contact the NHS when you thought you had COVID-19? Yes No No (d) Did you contact the NHS when you thought you had COVID-19? Yes No Yes No (d	Not going to place of work or education Yes, always Yes, sometimes Never	confusion confusion concentrating
using public transport, because of COVID-197 (select one) In to go (26' (a) Have you been offered a vaccination against COVID-19 since we last spoke to you? (a) Have you been offered a vaccination against COVID-19 since we last spoke to you? In to COVID-19 (select one) Don't know type Pfizer/Bio/NTech Monthal to the reasons (b, c) religious or cultural reasons) (b) Duty to have had coronavius (COVID-19) since we last spoke to you? If yes to QE (b) Type of vaccination (select one) Don't know type Pfizer/Bio/NTech Monthal to the figure of the figur		
Not going to other enclosed public spaces or using public transport Yes, siways Yes, sometimes D: COVID-19 INFECTION AND YOU D: CoviD-19 INFECTION AND YOU 1. Do you know or think you have had coronavirus (COVID-19) since we last spoke to you? (<i>If not sure, select No</i>) (b) Did you have any of the following symptoms? (answer Yes or No for each one) If yes, Cid you have any of the following symptoms? (answer Yes or No for each one) Fever Yes No No dy ou contact the NHS when you know of think? Yes No Audominal pain Yes No Additional CoviD-19 (e.g. 111, GP, Walk in Centre, A&E)? Yes No (d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk in Centre, A&E)? Yes No (d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk in Centre, A&E)? Yes No (d) Did you contact the NHS when you thought you had COVID-19? Yes No (d) Did you contact the NHS when you thought you had COVID-19? Yes No (d) Did you contact the NHS when you thought you had COVID-19? Yes No (d) Did you contact the NHS when you thought you had COVID-19? Yes No (e) Hyes; uad antited to hospital when you thought you had COVID-19? Yes No (d) Did you contact the NHS when you thought you had COVID-19? Yes No	using public transport, because of COVID-19? (select one)	
My face is already covered for other reasons (e.g. religious or cultural reasons) Image: Coverage of the coverag	Not going to other enclosed public spaces or using public transport	(go to Q7)
D: COVID-19 INFECTION AND YOU 1. Do you know or think you have had coronavirus (COVID-19) since we last spoke to you? (<i>if not sure</i> , select No) <i>if yes</i> : (a) On what date did you first know or think you had COVID-19: Yes No (b) Did you have any symptoms when you knew or thought you had COVID-19? Yes No (c) <i>ff yes</i> : Did you have any symptoms? (answer Yes or No for each one) (c) <i>ff yes</i> : (a) Last country visited (b) Did you have any of the following symptoms? (answer Yes or No for each one) Fever Yes No No Madache Yes No Meakness/firedness Yes No No Madache Yes No Shortness of breath Yes No Loss of sheell Yes No No (d) Did you contact the NHS when you thought you had COVID-19? Yes No No Cost of sheell Yes No (d) Did you contact the NHS when you thought you had COVID-19 (e.) 111, GP, Walk-in Centre, A&E? Yes No No Complete the UK since we last spoke to you (not including any tests done as part of this study)? Yes No 2. Have you admitted to hospital when you thought you had COVID-19? Yes No No Ceres version 11 FINAL bate: 7 June 2021 RAS Projet ID: 283248 CRPS Version 11 FINAL bate: 7 June 2021 IRAS Projet ID: 283248 Page: 3 of 4 Yes		
1. Do you know or think you have had coronavirus (COVID-19) since we last spoke to you? (<i>if not sure, select No</i>) If yes: (a) On what date did you first know or think you had COVID-19: If yes: (b) Did you have any symptoms when you knew or thought you had COVID-19? Yes No (b) Did you have any symptoms when you knew or thought you had COVID-19? Yes No (c) Mumber of doses received to date 1 2 3 (c) <i>If yes</i> : Did you have any symptoms when you knew or thought you had COVID-19? Yes No (d) Date of most recent vaccination 0 Fever Yes No Headache Yes No No Muscle ache Yes No Meesnes/tiredness Yes No No ausea/voniting Yes No No Loss of taste Yes No (d) Did you contact the NHS when you thought you had COVID-19? Yes No No Loss of smell Yes No (e) Were you admitted to hospital when you thought you had COVID-19? Yes No Yes No No D D D If West No CMF5 Version 11 FINAL Date: 7 June 2021 IBAS Project ID: 283248 Page: 3 of 4 CMF5 Version 11 FINAL Date: 7 June 2021 IBAS Project ID: 283248 OF		
If yes: (a) On what date did you first know or think you had COVID-19: Image: Construction of the constru		
If yes: (a) On what date did you first know or think you had COVID-19: (a) M M Z Q Q Z Y (b) Did you have any symptoms when you knew or thought you had COVID-19: (b) Did you have any symptoms when you knew or thought you had COVID-19? Yes No (c) If yes: Did you have any symptoms? (answer Yes or No for each one) (c) If yes: Did you have any symptoms? (answer Yes or No for each one) (c) Date of most recent vaccination (c) Date of most recent vaccination Fever Yes No No Muscle ache Yes No No Weakness/tiredness Yes No No Sore throat Yes No Abdominal pain Yes No Shortness of breath Yes No Loss of taste Yes No Loss of staste Yes No No (d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E?) Yes No Signature (study worker) Signature (study worker) Date (e) Were you admitted to hospital when you thought you had COVID-19 since we last spoke to you (not including any tests done as part of this study)? Yes No No Yes No No CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page		
(b) Did you have any symptoms when you knew or thought you had COVID-19? Yes No (c) <u>If yes;</u> Did you have any of the following symptoms? (answer Yes or No for each one) Yes No Fever Yes No Headache Yes No Weakness/tiredness Yes No Nusseal/vomiting Yes No Diarnoea Yes No Nusseal/vomiting Yes No Shortness of breath Yes No Loss of taste Yes No (d) Did you contact the NHS when you thought you had COVID-19? Yes No Complete the Xes or thought you had COVID-19? Yes No (e) Ware you admitted to hospital when you thought you had COVID-19? Yes No Yes No 2. Have you had a swab test of your nose and throat to test for COVID-19 since we last spoke to you (not including any tests done as part of this study)? Yes No CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248		
(c) <u>If yes</u> : Did you have any of the following symptoms? (answer Yes or No for each one) If yes: Or Source in the following symptoms? (answer Yes or No for each one) Fever Yes No Headache Yes No Weakness/tiredness Yes No Nausea/vomiting Yes No Diarrhoea Yes No Nausea/vomiting Yes No Cough Yes No Shortness of breath Yes No Loss of smell Yes No Loss of smell Yes No (d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E)? Yes No CoMPLETED BY: Name (study worker) D at D at Attract to the the did to a study worker) D at D at Attract to the the did to a study worker) D at Attract to the did to a study worker) D at Attract to the did to a study worker) D at Attract to the did to a study worker) D at Attract to the did to a study worker) D at Attract to the did to a study worker) D at Attract to the did to a study worker) D at Attract to the did to a study worker) D at Attract to the did to a study worker) D at Attract to the did to the did to the did to a study worker) <td< td=""><td></td><td></td></td<>		
Fever Yes No Headache Yes No Weakness/tiredness Yes No Abdominal pain Yes No Diarrhoea Yes No Nausea/vomiting Yes No Abdominal pain Yes No Diarrhoea Yes No Sore throat Yes No Loss of smell Yes No Shortness of breath Yes No Loss of smell Yes No Costs of used Yes No (d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E)? (e) Were you admitted to hospital when you thought you had COVID-19? Yes No 2. Have you had a swab test of your nose and throat to test for COVID-19 since we last spoke to you (not including any tests done as part of this study)? Yes No Yes No CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4		Fire (a) Last country visited
Weakness/tiredness Yes No Nausea/vomiting Yes No Diarrhoea Yes No Sore throat Yes No Carso frame Yes No Shortness of breath Yes No Loss of same Yes No Carso frame Yes No (d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E)? Yes No Signature (study worker) Signature (study worker) Date (e) Were you admitted to hospital when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E)? Yes No Yes No 2. Have you admitted to hospital when you thought you had COVID-19 since we last spoke to you (not including any tests done as part of this study)? Yes No CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 O		
Diarrhoea Yes No Sore throat Yes No Cough Yes No Shortness of breath Yes No Loss of taste Yes No Loss of smell Yes No (d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E)? Yes No D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D		
Shortness of breath Yes No Loss of smell Yes No (d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E? Yes No D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D		E. ADDITIONAL CONSENT - DO NOT Take additional consent il databasa is u
(d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E)? (e) Were you admitted to hospital when you thought you had COVID-19? (f) Yes No 2. Have you admitted to hospital when you thought you had COVID-19 since we last spoke to you (not including any tests done as part of this study)? (f) Yes No CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248		COMPLETED BY: Name (study worker) Signature (study worker) Date
(e) Were you admitted to hospital when you thought you had COVID-19? Yes No 2. Have you had a swab test of your nose and throat to test for COVID-19 since we last spoke to you (not including any Lests done as part of this study)? Yes No CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 OF	(d) Did you contact the NHS when you thought you had COVID-19 (e.g. 111, GP, Walk-in Centre, A&E)?	
2. Have you had a swab test of your nose and throat to test for COVID-19 since we last spoke to you (not including any tests done as part of this study)? Yes No CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 CRF5 Version 11 FINAL Date: 7 June 2021 CRF5 Versio		
CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 C		т
CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 C	tests done as part of this study)?	or of the second s
CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRF5 Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 C		ote
CRFS Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 Page: 3 of 4 CRFS Version 11 FINAL Date: 7 June 2021 IRAS Project ID: 283248 D		CI CI
	ыкто version 11 minut unte? / June 2021 IRAS Project ID: 283248 Page: 3 of 4	
		8

5

6

7

8

9 10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 35

36 37 38

39

40 41

42 43

Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohortreporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

			Page
		Reporting Item	Number
Title and abstract		°Z	
Title	<u>#1a</u>	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	<u>#1b</u>	Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background / rationale	<u>#2</u>	Explain the scientific background and rationale for the investigation being reported	3
Objectives	<u>#3</u>	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	<u>#4</u>	Present key elements of study design early in the paper	3-5
	Forp	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	Setting	<u>#5</u>	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3-5	BMJ Ope
	Eligibility criteria	<u>#6a</u>	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	3-5	n: first publis
	Eligibility criteria	<u>#6b</u>	For matched studies, give matching criteria and number of exposed and unexposed	n/a	shed as 10.1
	Variables	<u>#7</u>	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	3-5	136/bmjopen-20
	Data sources / measurement	<u>#8</u>	For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for for exposed and unexposed groups if applicable.	3-5	BMJ Open: first published as 10.1136/bmjopen-2021-054200 on 25 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright
26 27	Bias	<u>#9</u>	Describe any efforts to address potential sources of bias	3-5	ər 2021
28 29	Study size	<u>#10</u>	Explain how the study size was arrived at	3-5	. Dowi
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 4 55 56 57	Quantitative variables	<u>#11</u>	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	3-5	nloaded fror
	Statistical methods	<u>#12a</u>	Describe all statistical methods, including those used to control for confounding		n http://bmj
	3-5				open.b
	Statistical methods	<u>#12b</u>	Describe any methods used to examine subgroups and interactions	3-5	mj.com/ on .
	Statistical methods	<u>#12c</u>	Explain how missing data were addressed	3-5	April 23, 20:
	Statistical methods	<u>#12d</u>	If applicable, explain how loss to follow-up was addressed	n/a	24 by guest
	Statistical methods	<u>#12e</u>	Describe any sensitivity analyses		. Protected k
	3-5				у сору
58 59 60	Results	For p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		rright.

1 2 3 4 5 6 7 8	Participants	<u>#13a</u>	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.	5-6
8 9 10	Participants	<u>#13b</u>	Give reasons for non-participation at each stage	n/a
11 12 13	Participants	<u>#13c</u>	Consider use of a flow diagram	
14 15	n/a			
16 17 18 19 20 21 22	Descriptive data	<u>#14a</u>	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	5-6
23 24 25 26	Descriptive data	<u>#14b</u>	Indicate number of participants with missing data for each variable of interest	
20 27 28	n/a			
29 30 31	Descriptive data	<u>#14c</u>	Summarise follow-up time (eg, average and total amount)	
32 33	n/a			
34 35 36 37 38	Outcome data	<u>#15</u>	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.	
39 40	n/a			
41 42 43 44 45 46 47	Main results	<u>#16a</u>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	5-6
48 49 50 51	Main results	<u>#16b</u>	Report category boundaries when continuous variables were categorized	5-6
52 53 54 55	Main results	<u>#16c</u>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
56 57 58	n/a			
59 60		For p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Other analyses	<u>#17</u>	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	5-6
Discussion			
Key results	<u>#18</u>	Summarise key results with reference to study objectives	6-7
Limitations	<u>#19</u>	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	6-7
Interpretation	<u>#20</u>	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	6-7
Generalisability	<u>#21</u>	Discuss the generalisability (external validity) of the study results	6-7
Other Information			
Funding	<u>#22</u>	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1
This checklist was c	complet	listributed under the terms of the Creative Commons Attribution License CC- ed on 04. June 2021 using <u>https://www.goodreports.org/</u> , a tool made by the laboration with <u>Penelope.ai</u>	BY.
	Farm	peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	